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Background: Achilles tendon rupture (ATR) has a long healing period, which is challenging for patients
and clinicians. Platelet-rich plasma (PRP) is an autologous concentration of platelets thought to improve
tendon function recovery. Although preliminary research has indicated positive effects, there is, as yet,
no evidence of clinical efficacy from adequately powered robust clinical trials.
Objectives: The objectives were to determine the clinical efficacy of PRP in patients with acute ATR using
an objective mechanical muscle–tendon function measure and patient-reported outcome measures (PROMs),
and to determine which PRP components contribute to its mechanism.
Design: This was a multicentre, parallel-group, participant- and outcome assessor-blinded randomised
controlled trial (RCT) comparing PRP with placebo. Two embedded substudies investigated the PRP’s
quality and composition and its effects on healing tendon tissues.
Setting: This trial was set in trauma and orthopaedic surgery departments in 19 NHS hospitals in England
and Wales.
Participants: Adults with acute ATR presenting within 12 days of injury to be treated non-surgically were
eligible. Patients with platelet dysfunction or leg functional deficiency were excluded.
Interventions: Participants were randomised 1 : 1 to the PRP injection group or the placebo group
(dry needle in the rupture gap) by central computer-based randomisation using minimisation, stratified
by centre and age.
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Main outcome measures: The primary outcome measure was the Limb Symmetry Index (LSI) of work
during the heel-rise endurance test at 24 weeks. Secondary outcomes measures, collected at 4, 7, 13
and 24 weeks, were repetitions, maximum heel-rise height, Achilles tendon Total Rupture Score (ATRS),
quality of life (as measured using the Short Form questionnaire-12 items version 2), pain and participant
goal attainment. Needle biopsies of the affected tendon zone were taken under ultrasound guidance at
6 weeks from 16 participants from one centre. Whole blood was analysed for cell count. PRP was analysed
for cell count, platelet activation and growth factor concentration. The primary analysis was intention to treat.
Results: A total of 230 participants were randomised: 114 to the PRP group (103 treated) and 116 to the
placebo group (all treated). One participant withdrew after randomisation but before the intervention.
At 24 weeks, 201 out of 230 participants (87.4%) completed the primary outcome and 216 out of 230
participants (93.9%) completed the PROMs. The treatment groups had similar participant characteristics.
At 24 weeks, there was no difference in work LSI (mean difference –3.872; 95% confidence interval –10.454
to 2.710; p = 0.231), ATRS, pain or goal attainment between PRP- and placebo-injected participants. There
were no differences between the groups in any PROM at any time point or in complication rates, including
re-rupture and deep-vein thrombosis. There was no correlation between work LSI and platelet activation in
PRP, or erythrocyte, leucocyte or platelet counts in whole blood or PRP. Biopsies showed similar cellularity and
vascularity between groups.
Conclusions: This trial design and standardised PRP preparation gives the first robust RCT evidence about
PRP’s role in managing ATR, which suggests that PRP offers no patient benefit. Equally robust evidence to
investigate PRP application in tendon and soft tissue injuries is required. The 24-month follow-up will be
completed in April 2020.
Trial registration: Current Controlled Trials ISRCTN54992179.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership. The trial was supported
by the NIHR Biomedical Research Centre, Oxford, and the NIHR Fellowship programme.
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Achilles tendon rupture (ATR) is a common injury and leads to months of difficulty with walking. Thetendon attaches calf muscle to the heel. Most ATRs in the UK are treated by immobilising the lower
leg in a plaster cast or boot, followed by months of exercises to restore calf muscle strength. Absence from
work often lasts 2–3 months.
Platelets are the smallest blood cells and contain proteins that promote healing. Platelet-rich plasma (PRP)
is a concentrate of a patient’s own blood. Laboratory experiments suggest that it could improve tendon
healing. The effects of PRP on ATR healing in adults were investigated and recovery using patient-reported
measures was measured.
Using a computer, 230 patients from 19 hospitals were randomly allocated to receive either a PRP injection
or an imitation injection (placebo). Patients having surgical repair of the tendon were not included.
Participants were assessed before treatment and at 4, 7, 13 and 24 weeks after treatment. Information
was collected on calf muscle strength, quality of life, pain and whether or not participants recovered the
ability to do activities important to them. Any problems with their recovery were monitored. Participants’
blood was tested for proteins known to help healing. In 16 participants, tiny samples of tendon tissue
were taken to assess the healing.
There were no differences between participants injected with PRP and participants receiving the placebo in
calf muscle strength or in the patient-reported measurements. This meant that PRP did not improve tendon
healing during the 24 weeks. Complications were similar, with one out of 20 participants in each group
having a further tear of the tendon. The number of platelets in PRP did not influence the outcome.
The biopsies showed similar healing between the PRP and placebo groups.
It is concluded that PRP does not improve recovery from ATR over 24 weeks. Participants will be reassessed
at 2 years. PRP is widely used for other musculoskeletal problems and should be tested just as rigorously in
those contexts.
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Achilles tendon rupture (ATR) accounts for 20% of all tendon ruptures, and leads to significant health-care
and societal costs. The current treatment strategies are (1) surgical repair or (2) immobilisation in a cast
or boot. The mechanical and biological properties of healed tendons appear to never match those of the
original intact tendons, leading to a high risk of re-rupture (3–5%) or reduced function and a loss of,
on average, 63–108 days of work.
Platelet-rich plasma (PRP) is an autologous, supraphysiological concentration of platelets that also contains
other blood cells. Platelets play an important role at various stages of the repair process of tendon injury.
On activation, platelets release an ordered sequence of growth factors, cytokines and an array of bioactive
proteins over the lifespan of the platelets. Subsequently, this leads to recruitment of leucocytes, local stem
cells and tenocytes to initiate the healing process. Different methods of PRP preparation result in biological
component variability, which may influence its efficacy.
In published studies, there is substantial variation in the validity and type of outcomes measured, as well
as inconsistency in the observed effect size of PRP. The underpowered and inadequately designed studies
suggest that no definite conclusions can be made on PRP application as an adjunct to standard care in
the management of ATR. Prior to the PRP in Achilles Tendon Healing (PATH-2) trial, the authors of a
meta-analysis of PRP for orthopaedic conditions concluded that there was a need for adequately powered
studies using disease-specific and patient-important outcomes to investigate the effect of PRP (Sadoghi P,
Rosso C, Valderrabano V, Leithner A, Vavken P. The role of platelets in the treatment of Achilles tendon
injuries. J Orthop Res 2013;31:111–18).
Objectives
l To evaluate the clinical efficacy of PRP among patients with acute ATR using an objective measure of
mechanical muscle–tendon function.
l To evaluate the secondary outcome measures of patient-reported function, pain, participant goal
attainment and quality of life.
l To determine the key components of PRP that may contribute to its mechanism of action.




A multicentre, parallel-group, participant- and outcome assessor-blinded randomised controlled trial
comparing PRP with a placebo (imitation) injection in adults with acute ATR. Two substudies were embedded
in the main study to contribute to the understanding of the PRP mechanism in tendon healing:
l substudy 1 – PRP and whole-blood analysis
l substudy 2 – immunohistochemistry analysis of ultrasound-guided needle biopsies from 16 participants
at one centre (Oxford).
Setting
The trial was conducted in the trauma and orthopaedic surgery departments of 19 NHS hospitals in
England and Wales.
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Participants
Patients aged ≥ 18 years with an acute ATR attending an outpatient trauma or orthopaedic clinic within
12 days of sustaining the injury and suitable for non-surgical management were eligible for the trial.
The following patients were excluded:
l those with insertional or musculotendinous junction rupture
l those with previous tendon or ankle injury
l those with deformity to either lower leg
l those with a history of diabetes mellitus
l those with known platelet or haematological disorder
l those using systemic cortisone or anticoagulant treatment
l those with lower-limb gangrene/ulcers or peripheral vascular disease or hepatic or renal impairment
l pregnant or breastfeeding females
l those receiving radiotherapy or chemotherapy
l those with inadequate venous access
l those unable to participate in the trial or attend follow-up.
Interventions
Participants were individually randomised to receive either PRP injection or placebo (dry-needle insertion to
the tendon rupture gap), preceded by local anaesthetic, in a 1 : 1 allocation ratio. A central computer-based
randomisation system utilising minimisation, stratified by centre and age group (< 55 years or ≥ 55 years),
with a probabilistic element of 0.8 to reduce predictability, was provided by the Oxford Clinical Trials Research
Unit. Immediately after randomisation, up to 55ml of venous blood was taken from participants in the PRP
group and up to 5 ml was taken in the placebo group. Both interventions were delivered using the same
technique by a surgeon or extended-scope physiotherapist while maintaining a participant’s blinding.
Post injection, the remaining blood and PRP samples were sent to a central laboratory for substudy 1 analysis.
Sixteen participants (nine in the PRP group and seven in the placebo group) in one centre (Oxford) received
an ultrasound-guided biopsy for substudy 2 assays. All participants received standardised rehabilitation in
terms of the duration of ankle immobilisation and non-weight-bearing, and all were referred for physiotherapy.
Follow-up
Blinded outcome assessments were carried out at 4, 7, 13 and 24 weeks post randomisation. Following
signed consent being obtained, baseline data were collected and the participant was randomised; in most
cases, the injection treatment took place on the same visit. Primary outcome data were collected at a
24-week face-to-face appointment. At every time point, trial follow-up was carried out wherever
possible by blinded assessors unaware of treatment allocation.
Outcome measures
Muscle–tendon function assessed by the Limb Symmetry Index (LSI) of work (joules) during the heel-rise
endurance test (HRET) at 24 weeks was the primary outcome. Movement of the heel during the HRET in
each leg was captured using a computer-controlled linear encoder. The work LSI was calculated as follows:
(injured limb measurement/uninjured limb measurement) × 100.
Secondary outcomes were the maximum heel-rise height and number of repetitions during the HRET and the
patient-reported outcomes of function and symptoms [measured using the Achilles tendon Total Rupture
Score (ATRS)], quality of life [measured using the Short Form questionnaire-12 items (SF-12) version 2 acute],
pain (measured using the visual analogue scale and subscale from ATRS) and participant goal attainment
[measured using the Patient-Specific Functional Scale (PSFS)].
In substudy 1, whole-blood and PRP samples were analysed for cell count, platelet activation and growth
factor concentrations [i.e. platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1),
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and transforming growth factor
beta (TGF-β)]. In substudy 2, 16 participants in one centre had needle biopsy under ultrasound guidance
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at 6 weeks. Analysis included tissue morphology, proliferation, apoptosis, vascularity, metabolic indicators
and collagen ratio.
Analysis
The target sample size was 230 participants to provide 80% power. For the primary outcome, analysis
included a modified intention-to-treat (mITT) population, defined as all randomised intention-to-treat
participants with available work LSI data. Multivariate linear regression was used to investigate the effect of
PRP on ATR recovery. Sensitivity analyses were carried out using imputation of values for missing HRET data
to examine the robustness of the conclusions made from the analyses to address the primary aims of the trial.
A mITT population was also used for secondary outcome analyses. Linear mixed-effects regression models
were used to allow the data collected at all follow-up time points to be taken into account, adjusting for
pre-injury baseline scores when applicable. Data quality and effect of treatment received were assessed
using complier-average causal effect (CACE) analysis in place of the originally planned per-protocol analysis.
Complication events reported by participants were explored at two levels: serious adverse events and
adverse events (AEs).
For the two substudies, analyses were primarily descriptive, and the relationship between various
biomarkers and clinical outcomes was explored.
Results
A total of 230 participants were recruited between July 2015 and September 2017. Of these, 114 were
randomised to receive the PRP injection and 103 (90%) of these received the allocated treatment; 116 were
allocated to, and received, placebo. At 24 weeks, 201 out of 230 participants (87.4%) completed the HRET
to provide the work LSI primary outcome, and 216 out of 230 (93.9%) completed the patient-reported
outcomes. One participant withdrew from the trial. The average age of participants was 45 years; 75%
were male, with 69% of injuries occurring during sporting activity. The baseline characteristics of the
participants in the intervention groups were well matched.
Clinical trial results
There was no difference between the PRP and placebo groups at 24 weeks in the work LSI. In the PRP
group (n = 101), the work LSI was 34.9%, compared with 38.3% in the placebo group (n = 100) [adjusted
mean difference –3.872, 95% confidence interval (CI) –10.454 to 2.710; p = 0.231]. Statistical model
adjustment by stratification factors and the predefined prognostic variables had no impact on the results
attained. Sensitivity analyses accounting for participants with zero measurements for the uninjured limb
(unable to lift the heel at all) in the HRET, individuals missing heel-rise repetitions, individuals missing the
entire HRET data sets and compliance (i.e. CACE) showed that the results were robust.
There was no difference in secondary outcome results at 24 weeks: ATRS [PRP (n = 107), mean 64.9; placebo
(n = 109), mean 65.6; adjusted mean difference –0.543; 95% CI –4.899 to 3.813; p = 0.807] and PSFS (PRP,
n = 109, mean 7.198; placebo, n = 107, mean 7.495; adjusted mean difference –0.297; 95% CI –0.868 to
0.274; p = 0.291). ATRS-related pain scores were not different between the two groups in the follow-up
period (PRP, n = 109, mean 7.661; placebo, n = 107, mean 7.449; adjusted mean difference 0.212; 95% CI
–0.563 to 0.987; p = 0.592). Although no differences in the SF-12 physical component score were identified
between the treatment groups (adjusted mean difference 0.805, 95% CI –1.269 to 2.879; p = 0.447), mean
SF-12 mental component scores were lower in the PRP group than in the placebo group at 24 weeks
(adjusted mean difference –2.714, 95% CI –5.242 to –0.187; p = 0.035). There was no difference between
the PRP group and the placebo group in any of the patient-reported secondary outcomes at 4, 7 and 13 weeks.
Daily pain over the 2 weeks after injection was not different between the groups (PRP, n = 87, mean 9.5;
placebo, n = 93, mean 13.6; adjusted mean difference –4.019; 95% CI –10.302 to 2.265; p = 0.210). The
two groups had similar AE rates related to their Achilles rupture or injection. The number of participants
reporting at least one complication of any type related to their Achilles rupture or injection was 84 out of
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113 (74%) for the PRP group and 90 out of 116 (78%) for the placebo group. The numbers of participants
experiencing a re-rupture [PRP, 6/113 (5.3%); placebo, 4/116 (3.5%)] and deep-vein thrombosis [PRP, 6/113
(5.3%); placebo, 5/116 (4.3%)] were also similar.
Substudy 1 results
Whole-blood cell counts (red blood cells, white blood cells and platelets) showed that the two groups
were relatively well matched at baseline. Cell count analysis of PRP samples showed wide variation in cell
counts. The mean platelet count was 852.6 × 109/l [standard deviation (SD) 439.0 × 109/l], with a wide
range from 6.0 to 2903.0 × 109/l. The mean white blood cell count was 15.1 × 109/l (SD 10.3 × 109/l),
with a range of 1.7 to 65.3 × 109/l. Red blood cells were reduced remarkably (0.9 × 1012/l, SD 1.5 × 1012/l,
range 0.1 to 9.0 × 1012/l). The quality of the PRP samples in the majority of preparations was high, with
low levels of basal activation, and they were capable of activation and degranulation. TGF-β, VEGF, PDGF,
IGF-1 and FGF mean concentrations (133.4 ng/ml, 0.984 ng/ml, 55.49 ng/ml, 78.2 ng/ml and 112.5 pg/ml,
respectively) were high, as expected. Overall, PRP samples were therefore shown to be functional, with
the majority of platelets in the PRP preparations shown to be capable of activation and degranulation.
Parameters of baseline whole blood taken before intervention in both groups did not correlate with the
primary outcome measure at 24 weeks. PRP cell counts did not correlate with the primary outcome measure.
None of the growth factor concentrations showed any correlation with the work LSI.
Substudy 2 results
All biopsy results except one showed evidence of healing at 6 weeks; collagen fibre density was lower in
the PRP group. This did not correlate with differences in cellularity or vascularity as these parameters were
similar in both groups, suggesting equivalent healing processes.
Conclusions
Implications for health care
The main finding of the PATH-2 trial is that there was no evidence of benefit for PRP application in acute
ATR in terms of objective and subjective efficacy outcomes. The effect size estimates of the primary outcome
and end point and the consistency with patient-reported secondary outcomes during the follow-up strongly
support the validity of the conclusion that PRP does not improve the outcome of ATR management. Although
a health economic analysis was not carried out, applying PRP in ATR management would add to the cost of
standard care for no clinically measured improvement in the outcome. It is a no-value intervention in ATR
management.
Recommendations for research
The implication of the PATH-2 trial is that the indication for PRP application in other soft-tissue injuries
should be validated by similar robust clinical trials. The extent of functional asymmetry between injured
and uninjured legs in this trial was substantial. Optimising recovery of tendon–muscle function during
rehabilitation is therefore a recommended area of future investigation. An extended follow-up of PATH-2
participants at 2 years has started to evaluate longer-term patient-reported outcomes.
Trial registration
This trial is registered as ISRCTN54992179.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council
and National Institute for Health Research (NIHR) partnership. The trial was supported by the NIHR Biomedical
Research Centre, Oxford, and the NIHR Fellowship programme.
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Chapter 1 Introduction
In this chapter, we provide a background to the current management of Achilles tendon rupture (ATR),summarise the evidence base for the use of platelet-rich plasma (PRP) as a treatment and outline the
objectives of the PRP in Achilles Tendon Healing (PATH-2) trial.
Background
Achilles tendon
The Achilles tendon is the largest and strongest tendon in the human body. It is the tendon of the
gastrocnemius–soleus calf muscle complex. The Achilles tendon inserts to the calcaneum (heel bone),
forming the major plantar flexor and stabiliser of the ankle joint.1 The tendon is rounded and narrow in
shape at its midpoint and finally fans out at the insertion (Figure 1). The tendon fibres rotate around 90° as
they insert into the calcaneum. The narrowest part of the tendon is approximately 4 cm above the insertion.
The structure of the muscle–tendon unit allows for effective force to be generated when lifting the heel
during locomotive activities such as walking and running.1,2 The human Achilles tendon also stores and
returns energy.3 The tendon stretches in proportion to the force applied during the downwards motion of
the body and then recoils to release most of the energy stored (74%) during the upwards movement.
Blood supply to the tendon is variable but is least in the middle (mid-portion). The mid-portion is the
narrowest and a relatively avascular region within the tendon that corresponds to the most frequently
injured area. Degenerative changes, common with advancing age and metabolic and chronic diseases,
FIGURE 1 Anatomy of the Achilles tendon. The image on the left shows the left Achilles tendon projection at the
posterior aspect of the calf and heel (1, calf muscles; 2, Achilles tendon; 3, Achilles tendon insertion to heel); and
the image on the right is an illustration of the muscle–tendon unit (1a and 1b, gastrocnemius muscle medial and
lateral heads; 1c, soleus muscle; 2, Achilles tendon fibres; 2a, gastrocnemius Achilles fibres; 2b, soleus Achilles
fibres; 3, tendon insertion to the calcaneum).
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further compromise tendon vascularity and structure.4 Degenerative changes in the tendon decrease
collagen cross-linking and small repetitive tears weaken the tensile strength of the tendon. The Achilles
tendon ruptures when it is subjected to a load that exceeds its mechanical capacity.
Achilles tendon rupture epidemiology
The Achilles tendon is the most commonly injured tendon in the human body, accounting for 20% of
all tendon ruptures.5 The incidence of this injury is rising, due to increased engagement in high-impact
recreational sport, common particularly among men in the third and fourth decades of life.6,7 Other factors
that might increase the risk of injury include previous injury to the contralateral leg, direct injection of steroids
or administration of systemic corticosteroids and fluoroquinolones.8 In the UK, 11,000 injuries are reported
each year.9 In Denmark, an increase in incidence from 22.1 ATRs per 100,000 person-years in 1991 to
32.6 per 100,000 person-years in 2002 was reported by Gulati et al.10 The incidence of ATR is 12–18 cases
per 100,000 people per year for sedentary professionals.11 A Cochrane review12 reported rehabilitation and
work absence of 63–108 days, highlighting the socioeconomic burden of the injury.
The injury mechanism of ATR is mostly related to loading the tendon during weight-bearing physical
activity. Typical acute injuries result from rapid force shifts to the lower leg during sports. This can result
in partial or complete tear from direct (acute) trauma. During clinical assessment, patients often describe a
history of feeling a direct blow localised to the posterior aspect of the ankle with a sudden onset of pain,
swelling, bruising and difficulty with walking, usually during a sport activity. Physical examination of the
area commonly shows indentation at the locations of the tendon rupture, soft-tissue swelling and
tenderness, but these signs can be masked at the acute stage.
Spontaneous ruptures without a notable trauma, more common in ageing tendons, are typically associated
with pre-existing chronic, pathological changes in the tendon. Degenerative changes, such as poor vascular
supply, calcification, tendolipomatosis (replacement of tendon tissue with fat), necrosis (cell or tissue death),
hypoxia and mucoid degeneration, have been shown to be present in ruptured tendons not related to
sports.13 Once an acute tear to the tendon occurs, the structural, biochemical and functional properties of
the tendon are disrupted. Histopathological changes in the injured tissues have been reported. These include
high vascularity, collagen disorganisation and hypercellularity relatively close to the ruptured site. There is a
reduction in the number and diameter of type I collagen fibres, which are replaced with larger type III fibres.8
Clinically, a common method of examination to assess the integrity of the Achilles tendon is to lay the patient
prone on a plinth with their foot hanging over the edge. In this position, the tendon gap is usually palpable
and easy to observe, and on squeezing the calf muscle bulk, ankle plantarflexion can be anticipated if the
tendon is intact (Simmonds–Thompson test).14–16 These methods of assessment may result in misdiagnosis
when the tendon gap is filled with oedema or when a plantarflexion response is generated by other intact
muscles that also plantarflex the ankle (i.e. tibialis posterior and the peronei).17 However, significant plantar
flexion weakness on directed push-off, abnormal or poor gait pattern and inability to perform a heel rise on
the affected leg are often indicative of a complete tendon tear.18 Diagnosis is usually made clinically from
the history and physical assessments, but some clinical centres use ultrasound and magnetic resonance
imaging to support diagnosis. There are also treatment protocols that direct management using imaging
findings,10,18,19 but this is not currently routine practice in the NHS.
Healing of the tendon (repair and regeneration)
The healing of an injured tendon takes place in three overlapping, successive stages: inflammation, repair
and remodelling. These cellular responses are directed by numerous growth factors that are upregulated
and activated at various stages of the healing process.13,20 In the inflammatory stage, haematoma forms and
platelets release growth factors and bioactive proteins to attract inflammatory cells, including neutrophils.
This haematoma and the inflammatory cells eventually organise into granulation and scar tissue.13,20 In the
repair stage, recruitment, activation and proliferation of tenocytes and fibroblast begins in the injury site.
During this phase, neutrophil levels drop while macrophages continue to release growth factors that direct
cell activity. In addition, intrinsic and extrinsic tenocytes synthesise and establish a network of extracellular
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matrix composed of type III collagen fibres. The remodelling stage starts 1–2 months post injury and persists
for ≥ 12 months. Tenocytes and collagen mature and become aligned with the direction of stress. Over time,
the synthesis of collagen type III fibres decreases, while type I fibres become dominant and fibrous scarring
tissue remodel towards the original tendon tissue.13,20
Although tendons have the ability to heal after injury, the natural process is slow and incomplete.20 This
limited healing capacity of tendons may result from a combination of relatively poor vascularisation and
cellular turnover, changes to the matrix structure and the demanding mechanical environment of this
connective tissue.21–24 Poor vascularisation negatively affects the inflammation that is essential for the
restoration of the mechanical and biological properties of tendons during the healing process.25,26 Ageing
tenocytes – the dominant cell type in tendons – tend not to be able to facilitate the proper differentiation
of progenitor cells, resulting in ineffective healing. This leads to scar formation rather than tendon tissue
regeneration, which results in reduced tensile strength.13,20
The mechanical properties of the healed tendon do not fully recover, leading to weakness of the muscle
tendon unit and risk of re-rupture. Even with the best contemporary management, tendon injuries give rise
to substantial morbidity that lasts for many months and poses considerable challenges for clinicians and
patients during the lengthy healing and recovery period.27
Management of Achilles tendon rupture
The current treatment strategies for acute ATR are either surgical repair using sutures or non-surgical
management by immobilisation of the ankle using a boot or cast.19 Whether surgical or non-surgical
management of ATR is the optimal treatment approach is uncertain.7,19 The decision for the type
of management is often based on patient-related factors such as timing of presentation, comorbidities,
activity demands and previous tendon function.28 Notably, there is a decline in the proportion of tendons
treated surgically worldwide.7
Open, minimally invasive or percutaneous techniques for operative repair seem to show quicker return to
work and greater heel-rise height during physical assessments.29 However, surgical complications including
sural nerve injury, keloid formation, wound breakdown or infection are risks to be considered, although
they may be reduced when percutaneous surgical repair is used.29,30
Non-surgical management involves short periods (6–8 weeks) of ankle immobilisation starting in an equinus
(plantarflexed) ankle position in a cast, rigid boot or ankle orthoses.29 Recent developments of early functional
rehabilitation and range of motion protocol with early weight-bearing – using controlled ankle motion boots –
during non-surgical treatment have demonstrated similar surgical outcomes in terms of re-rupture rates
(3–5%) and function. However, non-surgical management does not increase the rate of re-rupture or
other complications compared with surgery.31–33 The inclusion of functional rehabilitation as an adjunct
to non-surgical management has not demonstrated improvement in biomechanical tendon properties or
tendon elongation, which influence plantarflexion strength.29,34 Although different surgical techniques and
non-surgical approaches can be used, evidence shows similar outcomes.35 These approaches are not known
to alter the existing biological regenerative pathway of the tendon, so the lengthy rehabilitation, reduced
function and re-rupture risk (3–5%) all remain.36 Functional impairments identified by calf atrophy, heel-raise
power compared with the opposite side, poor walking pattern (gait) and lower levels of physical activity are
reported as outcomes of these management strategies.37
Platelet-rich plasma
Although significant advancements in the clinical management of ATR have resulted in some improvements
in functional outcomes,38 there has been little progress made with regard to the restoration of the structural
and biomechanical integrity of an injured tendon to its original state. Thus, it is unsurprising that novel
therapies are being explored to diminish the degree and duration of morbidity. Biological adjuncts such as
PRP may augment the regeneration of a torn tendon. For example, platelet-derived growth factor (PDGF),
a derivative of PRP, seems to upregulate the synthesis of cells in tendons that direct optimal cellular repair
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response, which results in less scar tissue formation, stimulates healing and improves biomechanics.20
Evidence to support its clinical application in the management of musculoskeletal conditions remains
inconclusive.39
Platelet-rich plasma is an autologous derivative of whole blood that contains a higher concentration of
platelets and other bioactive compounds. PRP is produced by separating the red blood cells from the
platelets and other constituents in whole blood. The method of PRP preparation, such as centrifugation
or filtration; the concentration and volume of platelets and white blood cells (leucocytes); the activation
method; and growth factor levels have all been implicated in the local effects of PRP.39–41 Unsurprisingly,
the nature of the target tissue – acute, subacute or chronic – seems to affect local or systemic effects of PRP.42
As part of the normal injury response to an acute tendon rupture, platelets immediately contribute to the
blood clot that forms within the injured tissue. That response includes multiple growth factors released from
the platelets’ α-granules interacting with neutrophils, macrophages and other cells, working synergistically
to provide a wound healing mixture. This is part of a cascade within the injured tissue over a period ranging
from minutes to an average of several days.43,44 Active growth factors in PRP in the rupture site promote cell
motility and recruit undifferentiated stem cells and surviving tenocytes, which then proliferate to start the
healing process.45 The upregulation of growth factors such as vascular endothelial growth factors (VEGFs)
contained within PRP attracts vascular endothelial cells, which stimulate angiogenesis to restore normal
tissue conditions.46 PDGF, insulin-like growth factor 1 (IGF-1) and fibroblast growth factor (FGF) facilitate
proliferation of cells and hasten the start of the remodelling phase.47 Transforming growth factor beta
(TGF-β) promotes the formation of fibrous tissue and the expression, organisation and maturation of
collagen fibrils, enhancing the biomechanical strength of the tendon.48
Although there is evidence suggesting that leucocyte-poor PRP may produce better outcomes than
leucocyte-rich PRP (L-PRP), leucocytes contained in PRP seem to interact with the tissue of the tendon,
promoting healing by stimulating tenocytes within the injured area to produce their own growth factors.49
Furthermore, PRP assists the initiation of a cascade of steps that induce the synthesis of fibroblasts,
collagen fibrils, matrix-degrading enzymes and extracellular matrix. This sequential release of proteins is
amplified to recruit a diverse range of cell types to act on the injured tendon and disrupted blood vessels.
So far, conclusions from basic laboratory testing have indicated that PRP could be a novel agent for tendon
injury.44 Augmenting the natural biological healing pathway to improve patient recovery in Achilles tendon
injury may therefore have significant clinical implications on the health system at large by reducing
demands for surgical repair, accelerating rehabilitation, improving physical activity participation and
reducing re-injury rates.
Achilles tendon injury and platelet-rich plasma
Although PRP shows some promise as a treatment for promoting faster healing in tendons,20,50,51 the
potential enhancement of healing demonstrated in laboratory studies is yet to be evidenced in the patient
setting. The mechanisms of action through which PRP exerts its regenerative effects in humans are not
completely understood. A systematic review has summarised the evidence from animal experiments that
evaluated the use of platelets in the treatment of ATR.52 The authors reported a moderate beneficial effect
of PRP in the treatment of ATR in animal models. The observed effects were attributed to accelerated
and enhanced scar tissue maturation.52 An early systematic review of clinical trials of PRP in humans by
Taylor et al.50 reported faster healing and better function in the management of tendon and ligament
injuries. However, a more recent review by Gholami et al.51 reported no beneficial effects of PRP in the
management of sports injuries for pain or function compared with other management options.
A number of studies using different postoperative protocols have investigated the effect of platelets on the
treatment of ATR in humans. Two case reports, one of an injured athlete53 and the other of a complete
tear in an active 71-year-old male,54 showed positive effects of quick return to play after non-surgical
management. In a case–control study by Sánchez et al.,55 12 athletes with Achilles tendon injury were
treated with either PRP and surgery, or surgery alone; the PRP and surgery group (six athletes) achieved
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significantly quicker recovery and better functional outcome measures of greater range of motion and
return to play than those treated with surgery alone. However, this effect was seen only at 22 weeks, and
a difference was not found at the 1-year follow-up.56 Similarly, one small clinical trial (15 participants per
group) demonstrated no significant difference in structural and functional outcomes between surgery with
PRP and surgery alone.57 However, Zou et al.58 reported some improvement in isokinetic muscle strength,
ankle range of motion and measures of quality of life in a clinical study of 36 people with ATR comparing
surgery and PRP with surgery alone.
A randomised controlled trial (RCT) (n = 30) by Schepull et al.56 showed no difference for functional outcomes
or biomechanical tendon properties at 1-year follow-up when PRP with surgery was compared with surgery
alone.59 However, the authors also stated that a limitation in their platelet preparation technique and storage
of up to 20 hours resulted in only a 20% release of growth factors from the platelets. The level of activation to
release growth factors may have an impact on the regenerative process and could alter the clinical outcome.
We observed good activation rates of 69% as a measure of the quality of PRP used in a clinical pilot study,57
in which 20 patients were randomised to receive non-surgical treatment with or without PRP injection or
operative management with PRP gel, with standard rehabilitation for both groups. Achilles tendon Total
Rupture Score (ATRS) and the Victoria Institute of Sport Activity for Achilles (VISA-A) score showed significantly
better PRP group outcomes starting from week 3 to week 24 of follow-up.
All of these small clinical studies used PRP as an adjunct to surgical repair, which may have influenced the
effect of PRP on the tendon as there is additional surgical trauma and the mechanical effects of having a
suture across the tendon rupture gap. Overall, the results from RCTs with small numbers of participants
that have assessed PRP in ATR highlight that the current evidence is inconclusive.
Rationale for the PATH-2 study
Despite significant advances in the management of musculoskeletal injuries (e.g. novel operating techniques),27
slow recovery, morbidity and complication rates persist. PRP as an alternative, regenerative orthobiological
agent has gained popularity on the basis that it could augment the management of traumatic musculoskeletal
injuries. It is estimated that PRP is used to treat 86,000 tendon, ligament and muscle disorders annually in the
USA and Europe.60 There is also evidence to suggest that PRP injections are being administered in the NHS and
private medical practices in the UK.59
Platelet-rich plasma was initially used only as an adjunct during orthopaedic surgery, but in recent times it
has been applied in other areas of sports medicine. Basic experimental research has provided a biological
rationale for PRP, with encouraging results from histological and biomechanical assessments; however, its
clinical efficacy is yet to be confirmed by findings from studies with robust designs. Although PRP remains
an attractive treatment option, owing to its simplicity, patient acceptability, affordability and practicality,
the lack of proven clinical effects means that its use is controversial.
Although PRP has been shown to be relatively safe, preparation of PRP has yet to be standardised.61 For
example, some authors have suggested that administration during the early inflammatory stage of healing
may disrupt normal underlying physiological processes. This may result in the downregulation of certain
growth factors, such as TGF-β, which may promote the formation of fibrous tissue.61 Others did not find
a link with injection stage. Although injecting PRP concentrates may, in theory, increase the risk of infection
or exacerbate the underlying microbial activity within spontaneous ruptured tendons,23 no clinical impact
on outcome has been reported.36,50
There is substantial variation in the validity and type of outcomes measured, as well as inconsistency in the
effect size of PRP observed from published studies. The underpowered and inadequately designed studies
to date suggest that no definite conclusions can be made on PRP as a superior (or inferior) treatment
option over standard care in the management of acute ATR. A recent meta-analysis of PRP for orthopaedic
conditions62 stated the need for adequately powered studies using disease-specific and patient-important
outcomes to investigate the effect of PRP.
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We conducted a multicentre, pragmatic, parallel-group, blinded, placebo-controlled RCT to assess the
efficacy of PRP. Patients presenting with acute ATR receiving non-surgical management at orthopaedic
trauma surgery departments in the NHS in the UK were randomised to receive PRP or placebo (dry-needle
injection). PRP and rehabilitation were standardised. Two substudies of blood and tendon biopsy were
integrated into the main trial design to assess the components of PRP and to further explore the
mechanism of action on injured Achilles tendons.
Research objectives
l To evaluate the clinical efficacy of PRP among patients with acute ATR using an objective measure of
mechanical muscle–tendon function.
l To evaluate secondary outcome measures of patient-reported function, pain and quality of life.
l To determine in an exploratory substudy the key components of PRP that may contribute to its
mechanism of action.
l To identify the tissue-level parameters that PRP may alter to exert its effects in an exploratory
biopsy substudy.
INTRODUCTION
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Chapter 2 Clinical trial methods
Summary of study design
The PATH-2 trial was a multicentre, parallel-group, participant- and outcome assessor-blinded, randomised,
placebo-controlled trial with two embedded mechanistic substudies. In NHS hospitals in England and Wales,
patients with acute ATR for non-surgical treatment were randomised 1 : 1 to receive either an injection of
PRP into the rupture gap or a placebo injection (dry-needle insertion). In substudy 1, whole blood and PRP
were sent to a central specialised laboratory (Institute of Inflammation and Ageing, University of Birmingham)
for analysis. In substudy 2, immunohistochemical analysis was carried out on tendon biopsy material from
participants at one site (Oxford).
Settings and locations
Nineteen NHS hospital orthopaedic or trauma clinics in England and Wales screened and recruited
participants for this study:
1. Oxford University Hospitals NHS Foundation Trust
2. University Hospitals of Leicester NHS Trust
3. Taunton and Somerset NHS Foundation Trust
4. North Bristol NHS Trust
5. Cardiff and Vale University Health Board
6. Shrewsbury and Telford Hospital NHS Trust
7. Barts Health NHS Trust
8. University Hospitals Coventry & Warwickshire NHS Trust
9. Warrington and Halton Hospitals NHS Foundation Trust
10. Basildon and Thurrock University Hospitals NHS Foundation Trust
11. Royal Liverpool and Broadgreen University Hospitals NHS Trust
12. Peterborough and Stamford Hospitals NHS Foundation Trust
13. Abertawe Bro Morgannwg University Health Board
14. Aintree University Hospital NHS Foundation Trust
15. University Hospital of South Manchester NHS Foundation Trust
16. Sheffield Teaching Hospitals NHS Foundation Trust
17. Royal Devon and Exeter NHS Foundation Trust
18. Mid Cheshire Hospitals NHS Foundation Trust
19. Royal Surrey County NHS Foundation Trust.
The principal investigator (PI) at each site was a trauma and orthopaedic surgeon. Sites were selected after
completion of a site feasibility questionnaire, signed by the PI, which was used to assess whether or not
each site had the appropriate resources to deliver the project and meet recruitment targets. The PI supervised
implementation of the trial protocol at the site and co-ordinated with local physiotherapy services to provide
a standardised rehabilitation protocol and to arrange a blinded physiotherapist to be the assessor for the
primary outcome measurement. Confirmation of collaboration was provided in writing to the PI.
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Participants
Participant screening and eligibility assessment
All patients attending orthopaedic or trauma clinics with a suspected acute ATR were screened for inclusion
in the trial. Patients were identified for screening for the trial at this clinic visit, normally in the 12 days after
the initial visit to hospital, where the attending surgeon (or an extended-scope physiotherapist) confirmed
appropriateness for non-surgical treatment and trial eligibility.
Patients with acute ATR were eligible for the trial if they met all of the inclusion criteria and none of the
exclusion criteria.
Patients were eligible for inclusion if:
l they were willing and able to give informed consent for participation in the trial
l they were aged ≥ 18 years
l they were ambulatory prior to injury without the use of walking aids or assistance of another person
l they were diagnosed with an acute, complete ATR
l they presented and received trial treatment within 12 days post injury
l the decision had been made for them to receive non-surgical treatment
l they were able (in the investigator’s opinion) and willing to comply with all trial requirements
l they were able to attend a PATH-2 trial hospital site for the 24-week follow-up.
Patients were excluded if they:
l had an Achilles tendon injury at the insertion to the calcaneum or at the musculotendinous junction
l had a previous major tendon or ankle injury or deformity to either lower leg
l had a history of diabetes mellitus
l had a known platelet abnormality or haematological disorder
l were currently using systemic cortisone or a treatment dose of an anticoagulant (i.e. a prophylactic dose
for preventing thrombosis was not an exclusion criterion)
l had evidence of lower-limb gangrene/ulcers or peripheral vascular disease
l had a history of hepatic or renal impairment or dialysis
l were female and pregnant or breastfeeding
l were receiving, or had received within the previous 3 months, radiotherapy or chemotherapy
l had inadequate venous access for drawing blood
l had any other significant disease or disorder that, in the opinion of the investigator, might put the
participant at risk because of participation in the trial or might influence the result of the trial or the
patient’s ability to participate in the trial.
Members of the local research team informed the patient of the trial and carried out the informed consent
process, baseline data collection and randomisation.
Standard treatment for this non-surgical population is usually application of a plaster cast, orthopaedic
brace or splint during the clinic visit. The PATH-2 trial treatment options required the intervention to be
delivered before the definitive immobilisation method was applied. Therefore, the time frame between the
informed consent process and treatment was relatively short. To help raise awareness of the trial while
patients waited in the clinic, sites displayed trial posters and distributed participant information sheets (PISs)
in clinic waiting areas.
The attending clinician conducted a clinical examination and decided with the patient whether
management would be surgical or non-surgical. If non-surgical management was appropriate, and the
clinician confirmed the patient’s eligibility for the trial, the patient was informed of the trial and given a
PIS. The potential participants were allowed as much time as practically possible in this type of acute injury
CLINICAL TRIAL METHODS
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to consider the information, and had the opportunity to ask questions of the attending clinical team and a
member of the research team.
Consent was obtained by a member of the local research team who was trained in Good Clinical Practice
(GCP) and authorised by the PI to take consent: this could be a research nurse, physiotherapist or surgeon at
the local NHS trust, or a nurse assigned from the local National Institute for Health Research (NIHR) clinical
research network. The person taking consent presented the PIS and consent form to the participant by
means of a verbal discussion. The PIS detailed the exact nature of the trial, the implications and constraints
of the protocol, the known side effects and any risks involved in taking part. It was clearly stated that the
participant was free to withdraw from the trial at any time for any reason without prejudice to future care
and with no obligation to give the reason for withdrawal. The consent form was personally signed and
dated by the participant and by the person who obtained consent.
A copy of the signed consent form was given to the participant, and one copy was sent to the trial
co-ordinating team in Oxford to facilitate central monitoring. The original signed consent form was retained
in the medical notes, and a copy was held in the investigator site file. Consent forms were held in a secure
location separately from trial data. Permission was obtained to inform the participant’s general practitioner
(GP) of trial participation.
The PIS specified that a blood sample of up to a maximum of 55 ml may be taken. Only a maximum
amount was stated, as detailing the exact amount of blood withdrawn per treatment group would have
revealed treatment allocation; the amount drawn varied depending on treatment. The PIS also outlined
that the sample remaining after treatment for the PRP injection group and the sample for the placebo
group would be dispatched to a member of the central research team in the Institute of Inflammation and
Ageing, University of Birmingham, for analysis. Samples were anonymised before dispatch, and identified
using only the participant’s unique trial number. No laboratory results were reported back to participants
or the recruiting centre.
The PIS stated that name and contact details (including mobile phone number, telephone number and e-mail
address) would be collected to facilitate follow-up, full data collection and reporting of results. A copy of the
contact details would be sent to the trial co-ordinating team in Oxford. These details were used by the trial
team to check contact details through NHS Digital and to provide other basic trial-related information that
was needed for follow-up.
Permission was sought to allow access to participant data by responsible members of the University of
Oxford or the NHS trust for monitoring or audit of the trial to ensure that regulations were complied with.
The 24-week follow-up visit included the heel-rise endurance test (HRET) (primary outcome data collection).
The participant was asked to consent to video-recording (without audio) of their ankle and leg movements
at the time of the test. Consent for the video-recording was given on a second consent form so that the
participant could consent to participation in the trial without consenting to video-recording. The participant
personally signed and dated the consent form for video-recording, followed by the person who obtained
consent, and the procedures for handling the form were the same as for the intervention consent form,
detailed previously. Filming did not include the participant’s face; it focused on the legs, thus reducing the
risk of participants being identifiable from the film. The video file (or any still photographs from it) was
labelled with the unique trial number, and no identifying details were used. Permission was sought to send
the video file to the trial team in Oxford, where it was held and viewed by members of the research team.
At one site (Oxford) where participants were also asked to consent to the biopsy sample collection for
substudy 2, a version of the PIS was used that, in addition to the content described previously, invited the
patient to attend a separate trial visit during which a small sample of tendon tissue would be removed from
the injured tendon. A separate consent form that included consent to giving a tissue sample was provided
for these participants. The participant was under no obligation to give a tissue sample.
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Baseline assessments
Following signed consent, baseline data were collected and the participant was randomised. The injection
treatment took place during the same visit in most cases. A GCP-trained member of the local research
team oversaw the participant’s completion of the paper baseline questionnaire, which included:
l background information and demographics
¢ participant-reported questions including date of injury, which leg was injured, general health, current
medication, allergies, smoking status, alcohol use, sport activities, age, date of birth, sex, employment
status, type of employment, activities related to standing/walking/driving, any medication taken for
pain or inflammation, recreational activities prior to injury, the activity that led to the torn tendon,
previous rupture history, height and weight
l the Patient-Specific Functional Scale (PSFS)63,64
¢ participant reported – three important activities the participant was having difficulty with as a result
of their ATR (range is 0–10; a higher score indicates that the participant is closer to achieving their goal)
l the ATRS
¢ participant reported – questions specific to ATR (range is 0–100; a higher score indicates better function)
l the Short Form questionnaire-12 items (SF-12) version 2 acute
¢ participant reported – without injury (recall of pre-injury function and health state) (range is 0–100
for each of physical health and mental health; a higher score indicates a higher level of health)
l the SF-12 version 2 acute
¢ participant reported – with injury (current function/health state) (range as for pre injury)
l pain visual analogue scale (VAS)
¢ participant reported – baseline report of pain prior to treatment using a VAS (range of scores is
0–100; a higher score indicates greater pain).
The following events took place in the clinic during the baseline data-collection period:
l Blood sample – following randomisation, a blood sample was taken and the intervention was prepared
by a member of the local team according to allocated treatment.
l Participant contact details – contact details, including NHS number, were collected with a preferred time
to be contacted to organise trial follow-up.
l Pain diary – a pain diary was provided to the participant before leaving the clinic, to be completed at
home during the first 2 weeks following injection treatment, and to be returned to the trial office by
post using a Freepost account.
l General practitioner letter – the participant’s GP was informed of their participation in the PATH-2 trial.
CLINICAL TRIAL METHODS
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Randomisation
Participants were randomly allocated (1 : 1) to receive either the PRP injection or placebo. Randomisation
was carried out by a GCP-trained member of the local research team, either by telephone or via a secure
central computer-based system provided by the Oxford Clinical Trials Research Unit (OCTRU) randomisation
service. A randomisation method with minimisation algorithm using site and age group (< 55 years and
≥ 55 years) as strata and variable block sizes was used to ensure that sites and age groups were balanced
across the treatment groups. A probabilistic element of 0.8 was introduced to reduce predictability of
allocation. The service was accessible by telephone (during normal office hours: 08.00 to 17.00) and via a
secure randomisation website (24 hours per day/7 days per week). Details of the block sizes and allocations
were confidential and were known only by the trial statistician and OCTRU programmer.
Interventions
Once randomisation had taken place and the allocation was known to the research team, a blood sample
was taken from the participant and prepared as appropriate for the treatment to be delivered by an
unblinded research nurse (Figure 2).




PRP group: 55-ml blood sample taken














Placebo group: 5-ml blood sample taken






























FIGURE 2 Activities taking place on day of randomisation.
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Injection treatment was delivered in the outpatient clinic by a surgeon (consultant, registrar or clinical
fellow) or an extended-scope physiotherapist who was appropriately qualified, as delegated by the PI
(an orthopaedic surgeon). Full training in preparing and administering the intervention was given by central
trial office staff and detailed instructions were provided in an illustrated intervention and blood processing
manual, which was accessible to local staff when preparing the intervention and managing samples.
For participants in the PRP group, 5 ml of venous blood was drawn off into a 5-ml syringe, followed by
50 ml of venous blood into a 60-ml syringe that contained 8 ml of anticoagulant. The blood was drawn
slowly to avoid platelet agitation and early activation. The participant was asked to wait in an adjoining
room while the intervention was prepared. The 60-ml syringe was fitted into the trial-specific centrifuge
provided to all sites (MAG-200 MAGELLAN® Autologous Platelet Separator, Arteriocyte Medical Systems,
Hopkinton, MA, USA). A sterile, disposable PRP kit (MDK 300/MDK 300-1 platelet separation chamber,
Arteriocyte Medical Systems, Hopkinton, MA, USA) was placed in the centrifuge, and the centrifuge was
set to run to produce 8 ml of PRP, which was fed into a 10-ml syringe.
For participants in the placebo group, 5 ml of venous blood was drawn off into a 5-ml syringe. The
participant was asked to wait in an adjoining room while the intervention was prepared. An empty syringe
was prepared. The participant was not approached with the placebo intervention until a length of time
had passed, similar to the time taken to produce PRP.
For both groups, the participant was asked to return to the treatment room and to lie prone on a treatment
bed with the tendon exposed. The tendon gap was palpated clinically to determine the injection site and
the area was cleaned. Local anaesthetic (1–2 ml) was administered to the skin.
Participants in the PRP group were given a 4-ml injection of PRP into the tendon rupture gap. Participants
in the placebo group received a placebo injection: a dry needle of the same size was introduced via the
skin into the tendon tissue, held in the skin briefly and withdrawn without injecting anything so that the
biological haematoma was minimally disturbed.
For both groups, the injection area was covered with a dressing and the participant had application of a
plaster cast or an orthopaedic boot with the ankle immobilised in the equinus (plantarflexed) ankle position.
If a participant randomised to the PRP group was unable to receive a PRP injection for any technical reason
or if blood withdrawal failed, they received a placebo injection. This was recorded, and, whenever possible
the participant remained blinded to knowledge of their treatment group. Trusts followed their own policy
to manage deep-vein thrombosis (DVT) prophylaxis.
After injection delivery
The centrifuge produced 8 ml of PRP, of which 4 ml was injected into the participant’s Achilles tendon;
4 ml remained for laboratory analysis (see Chapter 4 for further details of the preparation of these samples).
Immediately after the intervention, a member of the local team prepared the remaining PRP (PRP group)
and the 5-ml whole-blood sample (PRP and placebo groups) for storage or dispatch. Samples were sent to
a member of the central team at the University of Birmingham research laboratory. A single, specialised
courier (Davies International, Hampshire, UK) was used for this purpose and a pre-paid account was
established with the courier to facilitate ease of sample transport.
The 4 ml of PRP that remained after injection (PRP group only) was prepared for dispatch to the laboratory;
1 ml of PRP was transferred to a microtube and stored at the site in a –70 °C freezer within 2 hours of
PRP production. These samples were collected by the dedicated courier at the end of recruitment and
transported to the central laboratory for analysis for substudy 1.
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In the PRP group, 1 ml of PRP was transferred to a microtube and placed in a trial-specific courier pouch;
2 ml of PRP was transferred into activation vials from a proprietary platelet-activation kit (CB kits, Platelet
Solutions Ltd, Nottingham, UK) supplied by the central trial office for platelet activation and fixation. The
platelet activation and fixation took around 5 minutes and full instructions were given in the intervention
and blood processing manual. When the process of platelet activation and fixation was complete, these
two tubes were placed in the courier pouch.
For both groups, the 5-ml venous whole-blood sample was transferred to a tube containing
ethylenediaminetetraacetic acid, an anticoagulant, and placed in the courier pouch. Thus, the courier
pouch contained four tubes if the participant was randomised to PRP (three tubes containing PRP and
one tube containing blood) and one tube if the participant was randomised to placebo (blood only).
The courier pouch was packaged in accordance with instructions in the intervention and blood processing
manual and the site contacted the courier for collection and next-day delivery service. Until collection,
the courier package was stored at room temperature.
Preparation of PRP and samples and courier dispatch were recorded on a blood tracking sheet. The original
version of this form was enclosed with the courier pouch for dispatch to the laboratory. A copy was sent
separately to the central trial office and a copy was retained at the site. Blood and PRP analysis results
were not reported back to the recruiting centre as they did not have an impact on future treatment.
Injection training
Training in the delivery of both the PRP injection and the imitation injection was provided by the trial team
and recorded on a PATH-2 trial training form (treatment related), which was signed by the clinician
receiving training and retained at the site. Training consisted of the provision of a training manual for all
sites. At most sites, a training video or training session by a PATH-2 trial trainer using the trial kit and trial
procedures was provided in addition to this manual. The PI at each site identified surgeons (or extended-
scope physiotherapists) to be trained, and recorded those who completed training on the site delegation
log. Only those individuals who were trial trained and listed on the delegation log were able to carry out
trial treatments. When the delegation log was updated, a copy was sent to the trial co-ordinating office
in Oxford. The PI at each site identified local staff who were responsible for preparing the blood and PRP
samples for treatment and for later dispatch. Only those individuals who were listed on the delegation log
as having this responsibility were able to carry out preparation of the blood and PRP and to manage blood
and PRP samples.
Monitoring intervention delivery
Intervention delivery was monitored centrally by PATH-2 trial staff. Site staff documented the intervention,
including preparation and processing of samples, using a blood sample and treatment case report form
(CRF) and a blood tracking sheet. Site staff were trained in completion of these forms by central trial staff.
The original blood tracking sheet was sent with the samples to the Birmingham laboratory as supporting
documentation for substudy 1. Copies of these completed forms were returned to the trial office and copies
were kept at the site.
On receipt of the two forms, trial office staff checked that the forms were fully and correctly completed,
that the intervention had been carried out by an individual whom the PI had identified on the delegation
log as suitably qualified and that the procedures had been completed within the time frame specified in
the intervention and blood processing manual. If any problems had occurred during the preparation of the
samples, intervention delivery or sample processing, the site was contacted to investigate whether or not a
protocol deviation had occurred and if additional training was required.
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Rehabilitation
All participants received standard care for their injury in accordance with local site procedures. Immediately
after treatment, the participant’s ankle was placed in a splint, orthopaedic brace or plaster cast. Rehabilitation
was prescribed by local members of the clinical and physiotherapy teams. However, it was necessary to
standardise key elements of rehabilitation in order to reduce the risk of efficacy interference due to
substantial variation in rehabilitation protocols. The standardisation for PATH-2 participants involved:
l ankle immobilisation in the equinus ankle position in a splint, orthopaedic brace or plaster cast for a
minimum of 3 weeks
l referral to physiotherapy for rehabilitation
l avoiding more than 6 weeks of rigid full-time immobilisation without ankle motion or weight-bearing.
Adherence to these guidelines was monitored by asking participants questions about their progress with
rehabilitation. Standardisation of specific elements of rehabilitation, such as the splinting method, when
weight-bearing commenced or specific exercises, was not mandated.
Outcomes
Primary outcome
The primary objective of the trial was to evaluate the clinical efficacy of PRP in acute ATR in terms of
muscle–tendon function. The primary outcome measure at 24 weeks post randomisation was the Limb
Symmetry Index (LSI) of the work performed by each lower limb in joules (J) during the HRET. The HRET is
a validated objective measure of Achilles tendon muscle unit function.65
The HRET involves repetitive concentric–eccentric muscle actions of the plantar flexors in a single-leg
stance until exhaustion, with performance quantified as (1) total work in J, (2) number of repetitions and
(3) maximum heel-rise height in cm.65 Total work was selected as the primary outcome measure because
this index provides a measure of plantar flexor muscle endurance and Achilles tendon function as it
incorporates the maximum height of each repetition. Total work (J) was computed as the product of body
mass (kg), total vertical displacement (m) and the constant 9.807 converting kilopond metres to joules.
To quantify performance, a linear displacement sensor (MUSCLELAB™, Ergotest Innovation A.S., Porsgrunn,
Norway) was attached to the participant’s heel during the test and recorded on software on a laptop
computer. A PATH-2-specific user interface version of the MUSCLELAB software was developed with the
manufacturer for ease of use in a multicentre trial. Key features of this software and more background on
the HRET development are described in further detail in Appendix 2.
Heel-rise endurance test procedure for PATH-2
At the 24-week follow-up visit, the HRET procedure was explained to each participant by the blinded
outcome assessor. Standardised participant information and instructions for the HRET involved the participant
watching a video demonstration of the HRET and reading standardised written instructions detailing their
expected conduct during the test and the test termination criteria. The standardised warm-up involved 5
minutes of usual-pace walking followed by 10 double-leg heel raises. Before testing each leg, the participants
were asked to stand on the box being used and were allowed to familiarise themselves with the expected
timing of heel raises by lifting both heels together.
The HRET was first carried out on the uninjured limb and then on the injured limb. The test started with
the participant standing on one leg on a 10° incline box (so that the ankle was in a dorsiflexed position)
with the cord from the linear encoder strapped to the participant’s heel (Figure 3).
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The following standardisation parameters were adopted:
l Ankle starting position of 10° dorsiflexion, produced by conducting the HRET on a custom-made 10°
incline box.
l Knee starting position of full extension.
l Height of each repetition to be as high as possible.
l Pace of 30 raises per minute, guided by a digital metronome.
l Balance support by the fingertips only.
l Strictly defined test termination criteria – participants either stopped (i.e. volitional task failure) or were
audibly instructed to stop with both feet flat on the box whenever any of the following test termination
criteria were observed: (1) inability to keep pace with the metronome, (2) inability to maintain full knee
extension of the standing leg or (3) using more than fingertip support. The desired end point was
volitional task failure; however, outcome assessors were encouraged to use verbal prompts whenever
the termination criteria were observed and to stop the test if the participant did not respond to two
consecutive prompts.
Secure data transfer and confidentiality were assured by copying the HRET data from the encrypted laptop
to an encrypted Universal Serial Bus (USB) drive that was sent to the trial office. Sites retained a copy of
the entire site HRET data set on the dedicated trial laptop.
Assessor training material consisting of high-quality training videos, which were made by the PATH-2 trial
team and produced by Oxford Medical Illustration (Oxford University Hospitals NHS Foundation Trust,
Oxford, UK), and a training and reference manual. Face-to-face training was delivered by a member of the
PATH-2 trial team to each outcome assessor prior to their first participant’s 24-week follow-up appointment.
FIGURE 3 A participant performing the HRET. The participant stands on 10° incline box with a cord attached to
their heel and connected to a linear encoder, and raises and lowers their heel repeatedly until fatigued.
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The linear encoder, a very sensitive device, recorded minimal movements that might not represent actual
heel rises; it could also pick up any additional movements of the heel (e.g. participants tend to step off the
box or lift the leg up at the end of the test). To dismiss potential measurement errors, two members of
the trial team, who were blinded to treatment allocation, independently reviewed videos of all assessments
for which participants consented to recording. The invalid heel-raise repetitions in the HRET data were
identified so that could they could be dealt with in the analysis (see Statistical methods).
Secondary outcome measures
The secondary outcome measures were as follows:
l The ATRS,66 a validated patient-reported outcome measure (PROM) incorporating 10 questions relating
to muscle strength, fatigue, pain and function at 4, 7, 13 and 24 weeks post treatment. The score
range is 0–100.
l The SF-12 version 2 acute, a health-related quality-of-life PROM67 at 4, 7, 13 and 24 weeks post
treatment. The scale consists of a 12-item short questionnaire that assesses eight different health
domains reflecting both the physical health (physical functioning, role participation with physical health
problems, bodily pain and general health) and the mental health (vitality, social functioning, role
participation with emotional health problems and mental health) of the evaluated participants.
l A daily pain diary, reported by the participant for 14 days beginning on the day of treatment, using a
VAS. The participant was asked to place a vertical mark on a 100-mm horizontal line between the
extremes of ‘no pain’ and ‘worst pain imaginable’. Trial office staff measured the distance to the
vertical mark and converted the distance to a daily measure (0–100) of pain.
l The pain component of the ATRS at 4, 7, 13 and 24 weeks post treatment. In the ATRS, the participant
was asked ‘Are you limited due to pain in the calf/Achilles tendon/foot?’ and invited to circle an integer
from 0 to 10 inclusive, 0 indicating major limitations/symptoms and 10 indicating no limitations/symptoms.
l The PSFS,63 a PROM indicating progress on self-selected recovery goals relating to daily activities affected
by the injury on an 11-point scale (0–10), at 4, 7, 13 and 24 weeks post treatment.
l The maximum number of repetitions (heel rises) recorded during the HRET68 at 24 weeks post
treatment.
l The maximum vertical displacement (cm) recorded during the HRET68 at 24 weeks post treatment.
Adverse events
Complication events reported by participants were explored at two levels: serious adverse events (SAEs)
and adverse events (AEs).
Serious adverse events
A SAE is an untoward medical occurrence that:
l results in death
l is life-threatening
l requires inpatient hospitalisation or prolongation of existing hospitalisation
l results in persistent or significant disability/incapacity
l is a congenital anomaly/birth defect
l is another important medical event.
Adverse events
Adverse events were events that were related to the trial treatment or conditions that did not require
specific time-critical reporting but were collected as part of standard data collection in the PATH-2 trial.
AEs were broken down further into foreseeable and unforeseeable AEs.
CLINICAL TRIAL METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Foreseeable AEs:
l bruising and discomfort at the venesection site
l mild discomfort or minor bleeding from the ATR site following injection
l technical complications of the lower-leg casting and splinting
l consequences of depending on walking aids
l syncopal (fainting) episode associated with venesection or tendon injection
l discomfort at the ATR site during rehabilitation
l swelling or bruising of the lower leg and foot
l deep-vein thrombosis in a lower limb
l re-rupture of the treated Achilles tendon (including any surgery on the Achilles tendon treated in the trial).
Unforeseeable AEs:
l serious infection at the ATR injection site
l skin breakdown or ulceration of the treated lower leg other than ‘plaster sores’
l severe pain requiring more than simple analgesia beyond 10 days after injection.
Events that were related to trial treatment and that were either foreseeable or unforeseeable were defined
as AEs.
Serious adverse events were reported to the chief investigator by the local research team using a SAE form
within 24 hours of their becoming aware of the event, the PI having assessed causality and relatedness.
Adverse events were reported to the central trial office on an AE form by site staff. In addition, participants
were asked in follow-ups to report any type of AE that they had experienced.
Blinding
Blinding during treatment preparation and intervention
This was a double-blinded (participant and primary outcome assessor) trial. Participants remained blind
to allocation throughout the trial. Those staff involved in treatment delivery were aware of treatment
allocation because of the nature of the intervention. The primary outcome assessors were not aware of
the allocation or treatment received.
Site staff were trained consistently to maintain blinding. Care was taken not to draw the participant’s
attention to the amount of blood taken as this could have indicated the intervention group. To facilitate
treatment blinding, preparation of the intervention took place in a location away from the treatment room, or
the participant waited outside, as there was a difference in the number of consumables handled depending
on treatment allocation. When the injection was prepared, it remained out of the participant’s view.
If a participant randomised to the placebo group was within listening distance of the centrifuge, the
centrifuge was run on a dummy cycle. The wait time for the participant was approximately 17 minutes;
this was the time taken to run the centrifuge to produce PRP. During the interventions, the participant was
requested to lie face down with their foot and ankle slightly off the edge of the bed, and there was an
option of placing a pillow on the back of the participant’s shoulders below the neck to help visually shield
the intervention procedure. The verbal cues used by site staff at the time of treatment delivery did not
refer to allocation and were the same for both groups.
Full guidance on ensuring that the correct amount of blood was withdrawn into the appropriate tube or
syringe while ensuring that the participant remained blinded to allocation was provided in the PATH-2 trial
intervention and blood processing training materials, which were retained in an area where they were not
visible to the public.
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Facilitating blinding immediately post treatment
The PATH-2 blood sample and treatment CRF collected confirmation that allocated treatment was received.
When a treatment other than that allocated was indicated on the CRF, the trial co-ordinating team
contacted the site for further details and recorded the details. Additional training or troubleshooting of any
issues was instigated when necessary.
In hospital notes and in the letter to the participant’s GP, it was recorded that an injection was delivered
according to the random allocation assigned, but the type of injection was not recorded.
To assess the completeness of participant blinding, after the 24-week trial questionnaire and HRET
assessments were completed, participants were asked which treatment they believed they received
(‘PRP injection’, ‘imitation injection’ or ‘don’t know’) and why they believed this, along with questions
around their experience of taking part in the trial. These data were used to compute two blinding indices
with 95% confidence intervals (CIs) (James et al.69 and Bang et al.70 blinding indices).
Blinded follow-up assessors
Throughout the trial, follow-up was carried out wherever possible by blinded assessors unaware of
treatment allocation. A physiotherapist or assessor who was blind to allocation carried out the 24-week
trial follow-up assessment, including the HRET.
Sample size
Sample size
The trial was powered on the work LSI from the HRET at 24 weeks post randomisation and on the ATRS.
There were no formal interim analyses of the outcomes planned for the PATH-2 trial. However, the Data
and Safety Monitoring Committee (DSMC) agreed to check the sample size assumptions when at least
half of the originally planned number of participants had completed the 24-week primary end-point
assessment because they were based on the findings of a single previous study conducted in a single
centre.65 This decision was documented in the statistical analysis plan version 1.0.
Original calculation of sample size
It was calculated that 214 participants (107 per treatment group) would provide 90% power to detect a
standardised difference of 0.5 in the HRET work measured by the work LSI at 24 weeks post randomisation
and with 5% (two-sided) significance allowing for 20% loss to follow-up. This was based on previous data
from the non-surgical arm of the 2010 study by Nilsson-Helander et al.,65 in which a clinically important
difference of 10 points with a standard deviation (SD) of 20 points was observed.
This sample size was also to provide 90% power and 5% (two-sided) significance to detect a standardised
effect size of 0.5 in the ATRS between the two treatment groups, based on a difference of 11% and a
SD of 21.4%.
Sample size review and recalculation
The DSMC agreed at their first meeting that the assumptions for the sample size should be reviewed after
approximately half of the participants had been recruited. This review would be a blinded estimate of
work LSI variability only. The first variability analysis was undertaken in October 2016 when half of the
participants had been recruited (n = 104). It was observed that the SD of the work LSI was smaller than
that used in the sample size calculation so no changes to the sample size were recommended (observed
SD 17.37, versus sample size SD 20). However, at this time only 27 participants had completed the primary
end-point assessment.
As of June 2017, approximately half of the participants had reached their primary end point and recruitment
was still ongoing. Therefore, to provide a more robust estimate of the actual variability of the work LSI,
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a further sample size assumption review was carried out. Using cleaned and validated data from 75
participants, the observed SD was 24, which was higher than that used in the sample size calculation.
Based on this observed SD of 24 (being aware that this could go up or down with the addition of further
participant data), we recalculated the sample size based on 80% power, which, allowing for 20% loss to
follow-up, required a sample size of 226 patients. The DSMC advised the Trial Steering Committee (TSC)
and trial management team during this process.
The trial continued to recruit to an agreed minimum of 230 participants (overshooting to account for
further minimal fluctuations in sample size assumptions), to ensure that there would be a minimum of
80% power for the primary outcome analysis. These approaches, and the reduction in trial power, were
supported by the TSC and by the funder.
Statistical methods
Software employed
All analyses outlined here and reported in Chapter 4 were undertaken using Stata® version 15.0 (StataCorp LP,
College Station, TX, USA).
Blinded analysis
Initial exploratory analyses were conducted on a blinded data set (not separated by treatment group) to
identify the presence of missing values and to clarify the distribution of continuous variables. These
analyses were also used to finalise trial populations and to aid in the identification of key prognostic
variables to be included in the adjusted analysis. All subsequent analyses described were conducted on an
unblinded data set. Following this blinded analysis, the statistical analysis plan was updated to incorporate
any changes.
Data validation
Initial analytical steps assessed the validity of the final, blinded data set. The first of these steps was to
manually check, when possible, the use of Stata for importing data and merging data sets for at least
20 participants who were randomly sampled. Once accurate importation was confirmed, data in the data
set were validated by checking for duplicate records, checking the values of the range of variables and
validating potential outliers against CRFs. Any discrepancies that could not be rectified were referred back
to the trial sites. Finally, the production of calculated variables using Stata was manually checked for at
least 20 participants who were randomly sampled.
Trial populations
Intention-to-treat population
This required the inclusion of all randomised participants, to be analysed in the groups to which they were
allocated. For the primary outcome, analysis included a modified intention-to-treat (mITT) population,
defined as all randomised intention-to-treat (ITT) participants with available work LSI data (i.e. at least one
valid repetition for each lower limb after HRET data validation by the blinded reviewers of the assessment
video files). For the secondary outcome, analysis also included a mITT population, defined as all randomised
participants who completed their 24-week follow-up questionnaires, analysed in the groups they were
allocated to.
Complier-average causal effect population
Complier-average causal effect (CACE) is an analytic approach that provides a robust estimate of the
treatment effect among compliant participants.71,72 Participants who received a ‘poor-quality’ PRP injection
(e.g. received PRP with concentrations of platelets lower than the concentration in their whole blood or did
not receive the PRP) in the PRP group were classified as not having received their allocated treatment.
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Descriptive analysis
All participants were included in descriptive analyses. Recruitment into the trial was explored, including the
numbers of individuals assessed, recruited, randomly assigned to the PRP injection or placebo, receiving
treatment, completing the trial protocol and analysed for the primary outcome. Any protocol deviations and
violations were investigated and issues with the screening data, including potential incidents of ineligible
patients being randomised, were explored. The proportion of unblinded assessors for each assessment
was assessed, and the James et al.69 and Bang et al.70 indices were calculated to determine whether or not
participants were successfully blinded to the intervention they received.
The baseline comparability of participant-level data for each of the treatment groups was summarised.
For baseline and follow-up data collected manually through the use of forms or questionnaires, data
compliance was explored; all available data collected from these forms were summarised and the proportion
of missing items from completed questionnaires was examined. Data-availability patterns for individual
variables were assessed both overall and for the two treatment groups separately to explore missing
information. Missing values were checked for consistency and the proportion of missing values per variable
was assessed. Differentiations were made between partially completed and fully missing outcome data.
For measures comprising multiple items, for example SF-12, pro-rata estimation of total and subscale scores
was employed for each treatment group, using the appropriate scale-specific scoring guidelines. Imputation
of data was utilised for sensitivity checking and is described in further detail in Primary outcome. Imputation
was carried out as recommended for each relevant questionnaire, with the imputation value determined
by the distribution of the underlying data. Methods utilised for imputation were assessed manually, when
possible, for at least 20 participants who were randomly sampled. Sensitivity analyses were conducted to
ensure that the missing-at-random assumption for imputation was met.
Comparisons of losses to follow-up were carried out. The proportions of participants defaulting or
withdrawing from the trial over the whole period of trial follow-up, and at each analysis time point,
were compared between the PRP and placebo groups. The importance of differences identified were
assessed using a chi-squared test. For all analyses, a p-value of < 0.05 was considered indicative of a
significant difference.
Quality assurance and compliance with the intervention, including any deviations from protocols prior to
and during the trial, were assessed. Treatment received was summarised by treatment groups, and time
frames for the steps with blood processing were explored to ensure that all participants received their
PRP injection within 2 hours of their blood sample being taken. The grade of the health-care professional
conducting the procedure was summarised. The importance of apparent differences in compliances was
assessed using a chi-squared test.
Finally, data quality and the effect of the treatment received were assessed using CACE analysis in place of
the originally planned per-protocol (PP) analysis, as this was deemed the optimal approach. As per the PP
analysis, CACE analysis allows for adjustment to account for participants whose received treatment either
complied or did not comply with that allocated to them; however, CACE analysis does so without assuming
that compliers are the same as non-compliers, as would be the case with a PP analysis. CACE analysis
retains information on the original treatment allocation that participants received, which allows us to forgo
the core assumption of a PP analysis – that receipt of treatment is random with respect to the outcome
predictors – and to enhance our understanding of the effect of PRP on ATR recovery. The decision to use
CACE was taken post finalisation of the statistical analysis plan but ahead of the end of follow-up and,
therefore, ahead of unblinding.
For the CACE analysis, compliance was defined as participants who received the intervention allocated
to them who had sufficient platelets present in their PRP sample to classify it as platelet rich (i.e. higher
platelet concentration in PRP than in whole blood). The results from the CACE analysis were reported with
standard errors, p-values and 95% CIs, and assessments were made to ensure that the primary outcome
estimation was captured within this range.
CLINICAL TRIAL METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
Standard care for ATR for all trial participants was unaffected by this trial. All participants should therefore
have had their injured lower limb immobilised, received a referral for physiotherapy, received delivery
of venous thromboembolism prophylaxis and received advice about when to start weight-bearing and
ankle-motion exercises. Compliance with these different aspects of standard care was compared between
treatment groups using a chi-squared test for categorical data and a Student’s t-test for continuous data.
Analysis of the primary outcome
The primary outcome for this trial was muscle–tendon function, measured by the LSI of maximum work,
performed during the HRET (see Primary outcome for more detail). The work LSI was calculated for all trial
participants, at 24 weeks (varying by –2 to +8 weeks) post randomisation, as follows:
LSI =
Injured limb HRET measurement
Uninjured limb HRET measurement
× 100. (1)
The proportions of individuals missing data for outcome and explanatory variables were explored, and
work LSI data for all participants were assessed for normality. Missing HRET data were defined and
handled as follows:
l Participants with true missing data – participants who were lost to follow-up and participants for whom
technical errors were experienced during HRETs. The participants who were lost to follow-up were any
participants who either did not attend their 24-week follow-up at all or did not remain at their
appointment to complete their HRET. The measurements for these participants were kept as missing.
l Participants with true zero measurements – participants who attempted to complete their HRET
assessment but their attempts were insufficient for the encoder to record any results. Zero
measurements for these participants were included for analysis.
l Participants with potential zero measurements – participants who did not attempt to complete their
HRET in at least one leg, despite attending the follow-up appointment. Zero measurements for these
participants were included for analysis.
The data followed a near-normal distribution, with a small elevation around zero due to participants defined
as having true and potential zero measurements. However, work LSI data did not require transformation
prior to inclusion in the final model as post-estimation assessments indicated that the distribution was
suitable for the regression technique employed. The impact of zero inflation of the primary outcome measure
was assessed using a two-parts model to (1) identify differences between participants with positive work
LSI results and participants with zero measures, and (2) identify the impact of the inclusion of participants
with zero measures on the primary outcome results. Mean work LSI differences, robust standard errors,
p-values and 95% CIs were reported and compared with the core primary outcome results for deviation
or interpretation changes.
An unpaired Student’s t-test was used to explore the unadjusted effects of PRP compared with those of
placebo.
Multivariate linear regression was used to investigate the effect of PRP on ATR recovery. The base-unadjusted
regression model was built using work LSI as the dependent variable and treatment as the key independent
variable. The principal analysis model built on this model by adjusting for participant age group and clustering
by trial site. Supplementary regression models were built, which adjusted for the effects of sex, body mass
index (BMI) and smoking status.
Sensitivity analyses were carried out using imputation of values for missing HRET data to examine the
robustness of the conclusions made from the analyses to address the primary aims. Missing HRET data
were handled using two approaches. The first was to employ simple imputation of the average concentric
displacement (upwards movement); this method was used for missing data associated with specific
repetitions of heel rise. The second method to handle missing data was to employ multiple imputation
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by chained equations; this was used to calculate work LSI for participants with data missing for entire
assessments. The multiple imputation using chained equations procedure created a series of complete data
sets (observed plus imputed data) in which analyses were carried out individually. The regression parameter
estimates plus corresponding standard errors obtained from the analyses of each of the 50 imputed data
sets were then combined using the Rubin’s rule approach. When models did not converge during the
multiple imputation process, some predictor preselection was carried out based on clinical expertise and
subject matter. Sensitivity analyses were employed to assess the assumptions made in preselecting these
predictor variables. The method utilised for multiple imputation inclusion was to use the stratification
variables already in the principal adjusted model and to further account for any variables with an R2 value
of ≥ 0.2 following correlation assessments. This resulted in three additional variables being selected:
whether or not the participant jogged or ran, undertook weight training or participated in squash before
their injury.
For all analyses, a two-sided p-value of 0.05 (5% significance level) was used to indicate evidence of
statistical significance.
Analysis of secondary outcomes
The number of repetitions and the maximum heel-rise height recorded during the HRET assessment were
explored as secondary outcome measures. Furthermore, four PROMs [pain as measured by the VAS (daily
over the 14 days immediately post treatment), ATRS, PSFS and the SF-12 mental and physical health scores]
were explored.
The ITT population was used for secondary outcome analyses.
Repeated-measures linear mixed-effects regression models were used to allow the data collected at all
follow-up time points to be taken into account. Time elapsed from the intervention to the outcome
measurements was included in the models as a random effect factor, considering that not all participants
had their follow-up assessments at exactly the same time. Mean differences and 95% CIs were examined.
All analyses were adjusted for the stratification factors included in the adjusted analysis of the primary
outcome. As pre-injury scores had been collected for the SF-12 data, the models for this PROM were built
so that the principal and supplementary analyses adjusted for these scores.
Sensitivity analyses were carried out on the overall ATRS data sets as this was the key secondary outcome.
The first of these analyses used the mITT population used in the primary outcome analysis to assess the
impact of selecting the mITT population used in the primary outcome analysis. The second applied multiple
imputation by chained equations for those participants with data missing with missing ATRSs. The multiple
imputation by chained equations technique that was applied to the ATRSs was the same as for the primary
outcome, although the additional variables selected for inclusion to inform the imputation were different.
The six additional variables used to build the imputation data sets in this situation were BMI as a continuous
variable, the date of the ATR, the date when the treatment was received, the date when a participant started
carrying out rehabilitation exercises (as recorded at week 13), whether or not a participant was jogging or
running by week 24 and whether or not a participant was carrying out ‘do it yourself’ (DIY), heavy housework
or gardening by week 24.
As with the primary outcome analysis, data quality was assessed using CACE on the overall ATRS data,
to examine the robustness of the conclusions made from the analyses.
Adverse events
The number of participants experiencing one or more AE of any type over the 24 weeks was explored. The
number of participants experiencing each specific type of AE over the 24 weeks was also analysed. The
number of separate complication events was not explored owing to the opportunity for re-reporting by
participants across the different follow-up time points and the nature of the events of interest.
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Patient and public involvement
The Efficacy and Mechanism Evaluation programme recognises the value of active involvement of public
contributors in research. In our patient and public involvement (PPI) work, we consulted trauma injury
patients at John Radcliffe Hospital. Our aim was to ensure that:
l interventions were acceptable to patients
l follow-up procedures reduced the patient burden while obtaining meaningful scientific data
l patient information sheets and questionnaires were easy to read and user-friendly.
The protocol73 was designed following a small-scale pilot study with the help of Achilles tendon injury
patients at the John Radcliffe Hospital and the Oxford Trauma User Group (OTUG), which is composed of
patients who have experienced the John Radcliffe Hospital orthopaedic trauma service and who volunteer
to engage on clinical and research issues. Recommendations of OTUG members were incorporated in the
original research proposal.
A questionnaire was sent to the OTUG members to explore opinions regarding the trial aims and procedures;
75 out of 105 replied to the survey. All responders indicated that the project might benefit patients with
ATR. Ninety per cent were happy with the trial design; some felt that the number of follow-up contacts
could be inconvenient. Taking that feedback, and experience of the pilot study,74 into account, follow-up
procedures were refined to reduce the number of follow-up contacts, thereby reducing participant burden.
Participant satisfaction with the intervention was explored in the pilot study. All 20 patients tolerated the
injection well and no side effects were reported. The use of needle biopsy under local anaesthetic, as in
substudy 2, was also reported during the pilot study to be acceptable.
A patient representative joined the TSC as a PPI representative to contribute to management of the
trial. One of the co-applicants acted as a mentor to the PPI representative, being available by telephone
before and after the meetings to help with interpretation of trial briefing documents. This provided an
opportunity for the PPI representative to raise issues prior to meetings, which she did, and if necessary the
mentor could raise issues on her behalf. All committee members were requested to use plain English in
meetings.
The PPI representative was also actively involved in designing the approach to patients and the text of
patient-facing materials (questionnaire and letters) and for the 2-year extended follow-up; the latter is
ongoing and not reported as part of this trial.
Members of the trial management team attended the INVOLVE conference and PPI research meetings.
Outcomes for patient and public involvement
In the main trial, participants reported satisfaction at the end of the trial in a post-assessment
questionnaire. We asked participants to rate their satisfaction with the trial on a five-point scale of
‘very dissatisfied’ to ‘very satisfied’. Eighty-nine per cent of participants declared themselves ‘satisfied’
or ‘very satisfied’. We invited comments on what could have improved their experience; the vast majority
who answered (n = 37) said ‘nothing’ and none asked for fewer forms, although five said that some
questions were not relevant and three asked for more information.
An adjustment to the statistical analysis related to how the pain score would be reported is an example of
how feedback from our PPI representative improved the conduct of the trial.
The PPI representative reviewed a graphical information slide to be used in future public-facing presentations.
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Overall, from participant feedback, we believe that our PPI involvement improved trial conduct and
participant experience.
Ethics approval and monitoring
Ethics approval
The trial was given a favourable opinion by the South Central – Oxford A Research Ethics Committee on
11 November 2014 (reference number 14/SC/1333) and each site was granted site-specific approval from
its NHS trust research and development department before trial commencement.
Data and Safety Monitoring Committee
The DSMC was established to safeguard the interests of trial participants, monitor the main outcome
measures including safety and efficacy, and monitor data quality and completeness. In accordance with the
DSMC charter, the DSMC received and reviewed information on the progress and data collection of the
trial and advised the TSC on the conduct of the trial.
Trial Steering Committee
The TSC provided expert oversight of the trial on behalf of the sponsor and funder. Through its independent
chairperson, the TSC also provided advice to the Trial Management Group (TMG), the funder and OCTRU
on all aspects of the trial.
Trial Management Group
The day-to-day management of the trial was overseen by a TMG comprising the chief investigator, the lead
research nurse at the lead site (John Radcliffe Hospital), the co-applicants, the trial statistician, research
physiotherapists and the trial manager.
Trial registration
This trial is registered with the International Standard Randomised Controlled Trial Number (ISRCTN)
Registry (ISRCTN54992179) and ClinicalTrials.gov (NCT02302664).
Summary of changes to the trial protocol
The changes to the project protocol are summarised in Table 1.
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TABLE 1 Changes to the protocol during the trial by version number
Protocol
version Date issued Details of changes made
1.0 10 September 2014 Not applicable as this was the first issue
2.0 12 February 2015 l Reference to ‘Blood Sample Handling Manual’ removed. Reader directed to the
trial intervention and blood sample training materials
l Registration details added (ISRCTN/ClinicalTrials.gov)
3.0 8 March 2016 l Addition of extended-scope physiotherapists, to reflect current NHS practice in
some trusts, to assess and treat ATRs and to conduct injections under the
supervision of the orthopaedic surgeon
l Changes to eligibility criteria: patient is eligible if within 12 days, not 7 days,
of injury; upper age limit removed
l Clarified some aspects of eligibility criteria: location of acute Achilles tendon injury
clarified; use of anticoagulant clarified
l Change to randomisation process to correct error in randomisation system:
from randomisation with stratification by strata (centre and age group) to using
minimisation, a dynamic computer-generated allocation system based on the
two strata. The change to randomisation was required because of imbalance in
participants’ age group stratum following a systems issue. The underlying systems
issue was fixed and a change to the randomisation strategy was implemented to
avoid this imbalance being preserved throughout the trial. The randomisations
allocated prior to the change were not altered. This approach was reviewed and
approved by the sponsor, DSMC, TSC and the ethics committee
l Collection of current medications data at baseline
l Inclusion in protocol of questions asked at 24 weeks on participant’s experience
of trial
l Clarification on excess treatment costs for trial-specific consumables
l DVT and re-rupture changed from ‘unforeseeable’ to ‘foreseeable’ AEs
4.0 8 March 2016 Removal of ‘draft’ from filenames, removal of draft watermark and removal of tracked
changes from documents for version 3.0
5.0 21 April 2017 l Inclusion of 2-year extended follow-up
l Dates changed to include 9-month extension, as agreed with the funder
6.0 24 July 2017 l Recruitment target changed from 214 to 230 after blinded review of variability in
primary outcome data to date
l Dates changed to include 2-month extension, as agreed with funder
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Chapter 3 Clinical trial results
Trial participants
A total of 230 eligible participants were recruited from July 2015 to September 2017 from 19 NHS hospitals
across England and Wales. Participants attended clinic visits at the time of randomisation (baseline) and
at 24 weeks post intervention, with the last 24-week visit taking place in March 2018. Participants were also
contacted by the trial team via telephone to complete follow-up questionnaires at 4, 7 and 13 weeks post
intervention. The trial ended when the recruitment target of 230 was reached.
One participant withdrew from the trial. This participant withdrew following randomisation but prior to
receiving any intervention. We therefore do not have baseline or follow-up data relating to this participant.
The reason given for withdrawal was that the participant had decided that they would prefer a surgical
intervention for their ATR. This participant had been randomised to the PRP injection group.
The number of participants at each stage of the PATH-2 trial, from assessment for eligibility through to
analysis, is presented in the Consolidated Standards of Reporting Trials (CONSORT) flow diagram in Figure 4.
Comparisons of losses to follow-up
A total of 27 participants (27/229, 11.8%) were lost to follow-up by the point of completing their HRET
assessment; these participants therefore did not contribute to the primary outcome analysis. Of these
participants, 24 (24/229, 10.5%) were true losses to follow-up, with 12 in the placebo group and 12 in
the PRP group. Of the 24 participants who failed to complete their HRET assessment:
l Eleven participants (11/24, 45.8%) completed all follow-up questionnaires up to and including their
24-week questionnaire but failed to remain to complete the assessment.
l Two participants (2/24, 8.3%) completed their 4-, 7- and 13-week follow-up questionnaires but not
their 24-week questionnaire.
l Four participants (4/24, 16.7%) completed their 4- and 7-week follow-up questionnaires but did not
complete their 13- and 24-week questionnaires.
l Two participants (2/24, 8.3%) completed only their 4-week follow-up questionnaires.
l One participant (1/24, 4.2%) completed only their 24-week questionnaire.
l Four participants (4/24, 16.7%) completed no follow-up past the baseline questionnaire.
These participants were spread across 10 sites and there were no discernible differences between them in
relation to their age, sex, BMI or smoking status.
In addition to these 24 participants, there were three participants (3/229, 1.3%) who were missing data
for their HRET assessments following a technical error. These participants therefore do not contribute to
the primary outcome analysis. However, it is worth noting that, although one of these participants did not
complete their 13-week follow-up questionnaire, all other questionnaires were completed.
There were no differences between treatment groups in whether or not a participant was lost to follow-up,
irrespective of whether participants who experienced a technical error were included in this cohort
[PRP injection, 12/113 (10.6%), vs. placebo, 15/116 (12.9%), difference –2.3%; p = 0.588] or not [PRP
injection, 12/113 (10.6%), vs. placebo, 12/116 (10.3%), difference 0.3%; p = 1.000].
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• Did not meet eligibility criteria,
   n = 741
• Eligible patient not approached,
   n = 92
• Declined to participate, n = 103
Analysed: primary outcome
(n = 101)





• Excluded, n = 1; all HRET repetitions
   deemed invalid at review
Analysed: secondary outcome
(n = 107)
• Lost to follow-up, n = 12
• Completed HRET, n = 101
• Completed 4-week PROMs, n = 111
• Completed 7-week PROMs, n = 107
• Completed 13-week PROMs, n = 104
• Completed 24-week PROMs, n = 109
• Lost to follow-up, n = 12
• Completed HRET, n = 101
• Completed 4-week PROMs, n = 108
• Completed 7-week PROMs, n = 108
• Completed 13-week PROMs, n = 104
• Completed 24-week PROMs, n = 108
Allocated to intervention
(n = 116)
• Received allocated intervention,
   n = 116
• Patient withdrew, n = 0





• Received allocated intervention,
   n = 103
• Patient withdrew, n = 1
• Received placebo, n = 10











• venesection unsuccessful, n = 5
• centrifuge technical issue, n = 2
• participant did not attend, n = 1
• disposable kit not available, n = 2
FIGURE 4 The PATH-2 trial CONSORT flow diagram.
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Trial populations
A total of 229 participants are included in the descriptive statistics, 113 of whom were in the PRP group
and 116 of whom were in the placebo group.
Intention-to-treat population
l Primary outcome (work LSI): a total of 201 participants were included, 100 of whom were in the PRP
group and 101 of whom were in the placebo group.
l Key secondary outcome (ATRS): a total of 216 participants were included, 107 of whom were in the
PRP group and 109 of whom were in the placebo group.
Compliance
Baseline, randomisation and treatment delivery forms
There were no differences between treatment groups in compliance with baseline, randomisation and
treatment delivery forms. Completion rates for all of these forms were 100% for both treatment groups.
Follow-up diaries and questionnaires
There were no differences between treatment groups in compliance with follow-up questionnaires and
diaries. A total of 180 out of 229 participants (78.6%) returned their pain diary for the first 2 weeks post
intervention. Completion of all follow-up questionnaires at weeks 4, 7, 13 and 24 was ≥ 90% in both
intervention groups.
Treatment allocation compliance
Nine per cent (10/113) of PRP group participants did not receive their allocated treatment, whereas all
placebo group participants received the intervention assigned to them. Treatment for participants in the
placebo group was dependent on the availability of the trial kit for this intervention. However, treatment
for participants in the PRP group was further dependent on the ability to withdraw sufficient whole blood
to produce the required 8-ml PRP sample. Therefore, it is not unexpected that a higher number of participants
in the PRP group did not receive their allocated treatment.
The reasons for participants in the PRP group not receiving their allocated treatment were:
l site staff being unable to take a blood sample from the participant (3/10, 30.0%)
l site staff not being able to take a blood sample of sufficient volume to produce PRP (2/10, 20.0%)
l technical issues encountered with centrifuge (2/10, 20.0%)
l participant not remaining on site to receive treatment (1/10, 10.0%)
l in-date PRP disposable kit not available (1/10, 10.0%)
l site staff unable to obtain PRP disposable kit (1/10, 10.0%).
In all PRP injection participants who were able to have blood samples drawn (103/113, 91.15%), the mean
time from taking the blood sample to their PRP injection was 42 minutes (range 12–105 minutes). This
breaks down to a mean of 28 minutes from taking the blood sample to producing the PRP sample (range
1–80 minutes) and a mean of 14 minutes from producing the PRP sample to receiving the injection (range
0–45 minutes). All PRP intervention participants who were able to have blood samples drawn received
their injection within the expected 2-hour time frame.
Grade of the clinician administering the treatment
A total of 75.5% of participants [total, 173/229; PRP group, 86/113 (76.1%), vs. placebo group,
87/116 (75.0%)] had their treatment administered by a consultant surgeon; 19.2% had their treatment
administered by a surgical registrar or research fellow [total, 44/229; PRP group, 19/113 (16.8%),
DOI: 10.3310/eme06120 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 12
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Alsousou et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
vs. placebo group, 25/116 (21.5%)], 1.3% had it administered by an extended-scope physiotherapist
[total, 3/229; PRP group, 1/113 (0.9%), vs. placebo group, 2/116 (1.7%)] and 1.7% had it administered by
any other grade of physiotherapist [total, 4/229; PRP group, 2/113 (1.8%), vs. placebo group, 2/116 (1.7%)].
Although we do not have any information for 2.2% of participants (5/229), there were no discernible
differences between groups in relation to the grade of clinician administering the treatment (p = 0.706).
Compliance with standard care
Compliance with standard care is reported in Table 2. There were no discernible differences between
treatment groups in compliance or in the use of venous thromboembolism prophylaxis [PRP group, 56/113
(49.5%), vs. placebo group, 58/116 (50.0%), difference –0.4%, p = 0.891]; the use of a below-knee cast
[PRP group, 47/113 (41.6%), vs. placebo group, 55/116 (47.4%)] or splint/brace [PRP group, 64/113 (56.6%),
vs. placebo group, 61/116 (52.6%)] to immobilise the ankle (p = 0.443); or in the receipt of a physiotherapy
consultation within 7 weeks [PRP group, 64/113 (56.6%), vs. placebo group, 68/116 (58.6%)] or 13 weeks
[PRP group, 100/113 (88.5%), vs. placebo group, 100/116 (86.2%)] (p = 1.000).
The date a participant started weight-bearing was recorded at the 4-week and 7-week follow-ups, and the
date they started ankle-motion exercises was recorded at 7 and 13 weeks. It was assumed that participants
remembered the date they were weight-bearing or exercising their ankle better if the time point was closer
to it. The time to start weight-bearing and the time to start ankle exercises was calculated as the date
reported minus the date the ATR occurred. The date reported was determined to be the earliest date
reported by the participant that this activity took place. To allow for the fact that participants may have
stopped either weight-bearing or exercising their ankle between questionnaires, participant binary responses
as to whether or not they were carrying out an activity were taken into account, and if participants answered
‘yes’ in the earlier questionnaire and ‘no’ in the later questionnaire, their reported date was not included.
TABLE 2 Summary of treatment received, by intervention group
Treatment received
Intervention group
Total (N= 229)PRP (N= 113) Placebo (N= 116)
Venous thromboembolism prophylaxis use, n (%)
No 54 (47.79) 58 (50.00) 112 (48.91)
Yes 56 (49.56) 58 (50.00) 114 (49.78)
Missing 3 (2.65) 0 (0) 3 (1.31)
Method of ankle immobilisation, n (%)
Below-knee cast 47 (41.59) 55 (47.41) 102 (44.54)
Splint/brace 64 (56.64) 61 (52.59) 125 (54.59)
Missing 2 (1.77) 0 (0) 2 (0.87)
Physiotherapy consultation received, n (%)
Within 7 weeks of injury 64 (56.64) 68 (58.62) 132 (57.64)
Within 13 weeks of injury 100 (88.50) 100 (86.21) 200 (87.34)
None reported by 13 weeks 4 (3.54) 4 (3.45) 8 (3.49)
Missing at 13 weeks 9 (7.96) 12 (10.34) 21 (9.17)
Time to starting weight-bearing (days), n; mean (SD) 96; 27.04 (24.12) 93; 27.70 (16.10) 189; 27.36 (15.24)
Time to starting ankle-motion exercises (days), n; mean (SD) 104; 47.40 (19.57) 103; 48.48 (19.97) 207; 47.94 (19.73)
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Following from the creation of the described time to weight-bearing and time to ankle-exercising variables,
assessments of their distributions demonstrated that they did not significantly differ from normal. Therefore,
differences in time taken to complete these tasks between treatment groups were assessed using Student’s
t-test; there were no differences in the time to weight-bearing between the PRP group (mean 27.0 days,
95% CI 24.1 to 30.0 days) and the placebo group (mean 27.7 days, 95% CI 24.4 to 31.0 days) (PRP group
vs. placebo group mean difference –0.7 days, 95% CI –3.7 to 5.0 days; p = 0.768) or in the time taken
to start ankle-motion exercises between the PRP group (mean 47.4 days, 95% CI 43.6 to 51.1 days) and
placebo group (mean 48.5 days, 95% CI 44.7 to 52.4 days) (PRP group vs. placebo group mean difference
–1.1 days, 95% CI –4.2 to 6.5 days; p = 0.672).
Descriptive analyses
The baseline characteristics of participants according to their intervention group are presented in Table 3.
Participants in both intervention groups are remarkably similar in all characteristics, with no observable
between-group differences.
Information on the stratification factors (age group and trial site) and other prognostic factors of interest
by intervention group are presented in Table 4. This table demonstrates that there are clear differences
between the levels of the subgroups; for example, more participants in this trial were aged < 55 years
than ≥ 55 years and there were notably more male participants than female participants in this trial.
However, there are no noteworthy differences between the intervention groups.
On exploration, it was found that only around 8.0% (13/163) of participants questioned were regularly
taking medications that could have an impact on their platelet function, with similar low proportions of
participants taking such medications in each intervention group [PRP group, 8/86 (9.3%)a, vs. placebo
group, 5/91 (5.5%)].
Pain levels at their injection site as reported by participants – relating to the need for more than simple
pain relief – were explored. Only 2.6% of participants (6/229) reported experiencing severe pain at their
injection site, with too-small numbers of participants to detect any difference between the PRP group
(4/113, 3.5%) and the placebo group (2/116, 1.7%). For more details, see Appendix 3.
The academic and employment characteristics of participants prior to their injuries were explored. These
explorations related to participants’ employment or academic status, the type of work undertaken and the
time participants spent on their feet or driving. There were no differences between the two intervention
groups in relation to any of the academic or employment-related characteristics investigated. For more
information, see Appendix 3.
TABLE 3 Baseline characteristics of participants, by intervention group
Baseline characteristics
Intervention group
Total (N= 229)PRP (N= 113) Placebo (N= 116)
n Mean SD n Mean SD n Mean SD
BMI (kg/m2)a 113 27.69 5.29 114 27.25 4.22 227 27.47 4.78
Age (years) 113 45.90 13.74 116 45.16 12.43 229 45.53 13.07
Alcohol consumption (units) 113 9.90 11.33 116 10.47 10.37 229 10.19 10.83
Days since injury 113 5.35 2.95 116 5.20 3.08 229 5.27 3.01
a Two participants who were missing baseline measurements of weight had measurements for this variable taken at later
follow-up dates that were used to calculate BMI for the advanced analyses, to prevent exclusion.
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TABLE 4 Stratification factors and sociodemographic characteristics of participants, by intervention group, as used
in adjusted analyses
Participant characteristics
Intervention group, n (%)
Total (N= 229), n (%)PRP (N= 113) Placebo (N= 116)
Centrea,b
John Radcliffe Hospital, Oxford 21 (18.58) 22 (18.97) 43 (18.78)
Musgrove Park Hospital, Taunton 9 (7.96) 8 (6.90) 17 (7.42)
Southmead Hospital, Bristol 7 (6.19) 9 (7.76) 16 (6.99)
Llandough Hospital, Cardiff 0 (0) 1 (0.86) 1 (0.44)
Royal London Hospital 7 (6.19) 8 (6.90) 15 (6.55)
Leicester Royal Infirmary 22 (19.47) 21 (18.10) 43 (18.78)
University Hospital Coventry 5 (4.42) 5 (4.31) 10 (4.37)
Warrington Hospital 3 (2.65) 2 (1.72) 5 (2.18)
Basildon University Hospital 9 (7.96) 9 (7.76) 18 (7.86)
Royal Liverpool Hospital 6 (5.31) 7 (6.03) 13 (5.68)
Peterborough City Hospital 6 (5.31) 5 (4.31) 11 (4.80)
Morriston Hospital, Swansea 3 (2.65) 4 (3.45) 7 (3.06)
University Hospital Aintree 2 (1.77) 1 (0.86) 3 (1.31)
Wythenshawe Hospital, Manchester 3 (2.65) 5 (4.31) 8 (3.49)
Northern General Hospital, Sheffield 3 (2.65) 4 (3.45) 7 (3.06)
Royal Devon and Exeter Hospital, Exeter 1 (0.88) 1 (0.86) 2 (0.87)
Royal Surrey Hospital, Guildford 1 (0.88) 1 (0.86) 2 (0.87)
Leighton Hospital, Crewe 5 (4.42) 3 (2.59) 8 (3.49)
Age (years)a,b
< 55 86 (76.11) 88 (75.86) 174 (75.98)
≥ 55 27 (23.89) 28 (24.14) 55 (24.02)
Sexb
Female 25 (22.12) 32 (27.59) 57 (24.89)
Male 88 (77.88) 84 (72.41) 172 (75.11)
Lower limb injured
Right 49 (43.36) 48 (41.38) 97 (42.36)
Left 64 (56.64) 68 (58.62) 132 (57.64)
BMI (kg/m2)c
Normal weight (18.5–24.99) 40 (35.40) 39 (33.62) 79 (34.50)
Overweight (25–29.99) 43 (38.05) 46 (39.66) 89 (38.86)
Obese (30–39.99) 30 (26.55) 31 (26.72) 61 (26.64)
Smoking statusb
Smoker 14 (12.39) 13 (11.21) 27 (11.79)
Ex-smoker 28 (24.78) 38 (32.76) 66 (28.82)
Never smoked 71 (62.83) 65 (56.03) 136 (59.39)
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The activity levels of participants before they experienced their rupture and the activity being undertaken when
the rupture occurred were explored (Table 5). The majority of participants (157/229, 68.6%) injured themselves
during sport. As with previous baseline variables, there were no clear differences between intervention groups
in relation to their pre-injury activity levels or the activity being undertaken when the injury occurred.
Analyses to address primary aims
Missing data assessments
Missing data explorations were carried out to maximise inclusion in the final analysis. The final classification of
participants with missing data following these explorations is given in Table 6. (For information on how missing
data were classified, see Chapter 2, Analysis of the primary outcome.)
Primary analysis outputs
There were three data sets available for the analysis of the primary outcome:
1. all available HRET assessments
2. all available HRET assessments that were deemed valid on review of video footage (see Chapter 2,
Primary outcome, for more information on the validation review)
3. all available HRET assessments that were deemed valid on review and included only participants with
assessments available in both legs.
The primary outcome analysis focuses on data set 3 (all valid HRETs available on both legs).
Explorations of the mean work exhibited during the HRET assessment in participants’ injured and uninjured legs
on all three data sets were carried out. Basic explorations of the subsequent measure for work LSI in participants
with measurements in both legs were undertaken. These explorations demonstrated that the mean work LSI
and subsequent HRET measurements for both intervention groups were very similar.
Focusing on the third data set, the mean work LSI in the injured leg was lower in both the PRP group
(675.2, SD. 622.3) and the placebo group (748.2, SD 630.3) than the mean work LSI in the uninjured legs
in the PRP (1783.8, SD 838.8) and placebo (1825.5, SD 796.2) groups. Comparing the subsequent work
LSI measurement in the PRP group (mean 34.9) with the work LSI measurement in the placebo group
(mean 38.3) using the Student’s t-test demonstrated no difference between these two groups (unadjusted
PRP group vs. placebo group difference –3.467, 95% CI –10.979 to 4.246; p = 0.384). These explorations
demonstrate that the work LSI measurements for both groups are very similar.
TABLE 4 Stratification factors and sociodemographic characteristics of participants, by intervention group, as used
in adjusted analyses (continued )
Participant characteristics
Intervention group, n (%)
Total (N= 229), n (%)PRP (N= 113) Placebo (N= 116)
Use of antiplatelet medicationd
Yes 8 (7.08) 5 (4.31) 13 (5.68)
No 78 (69.03) 86 (73.27) 163 (71.18)
Not askede 27 (23.89) 26 (22.42) 53 (23.14)
a Used as a stratification factor in adjusted analyses.
b Included in fully adjusted analyses.
c Included in fully adjusted analyses as a continuous variable.
d Medications taken: apixaban, aspirin, clexane, clopidogrel, dalteparin, dipyridamole, fragmin and pradaxa.
e Participants who had their baseline questionnaire administered before antiplatelet medication use was included in
the form.
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TABLE 5 Physical activity of participants before and during their injury, by intervention group
Activity type
Intervention group, n (%)
Total (N= 229), n (%)PRP (N= 113) Placebo (N= 116)
Pre-injury activities
Fitnessa
More than once/week 100 (88.50) 105 (90.52) 205 (89.52)
Less than once/week 10 (8.85) 10 (8.62) 20 (8.73)
Never 3 (2.65) 1 (0.86) 4 (1.75)
Ball sportsb
More than once/week 24 (21.24) 25 (21.55) 49 (21.40)
Less than once/week 22 (19.47) 21 (18.10) 43 (18.78)
Never 67 (59.29) 70 (60.34) 137 (59.83)
Racquet sportsc
More than once/week 8 (7.08) 15 (12.93) 23 (10.04)
Less than once/week 21 (18.58) 20 (17.24) 41 (17.90)
Never 84 (74.34) 81 (69.83) 165 (72.05)
Non-sporting activityd
More than once/week 65 (57.52) 67 (57.76) 132 (57.64)
Less than once/week 28 (24.78) 34 (29.31) 62 (27.07)
Never 20 (17.70) 15 (12.93) 35 (15.28)
Mechanism of injury
During sports 81 (71.68) 76 (65.52) 157 (68.56)
Heavy DIY, housework, gardening, etc. 1 (0.88) 3 (2.59) 4 (1.75)
Other 31 (27.43) 37 (31.90) 68 (29.69)
DIY, do it yourself.
a Fitness activities = cycling, jogging/running, walking, weight training, aerobics/keep-fit and athletics.
b Ball sports activities = football, rugby, hockey and netball.
c Racquet sports activities = tennis, squash and badminton.
d Non-sporting activities = heavy DIY, housework, gardening and other activities not included above.
TABLE 6 Classifications of participants with missing HRET data, by intervention group
Missing data classification
Intervention group, n (%)
Total, n (%)PRP Placebo
True missing data 12 (10.62) 15 (12.93) 27 (11.79)
Loss to follow-up 12 (10.62) 12 (10.34) 24 (10.48)
Technical errors 0 (0) 3 (2.59) 3 (1.31)
Participants with true zero measurements 9 (7.96) 11 (9.48) 20 (8.73)
Participants with potential zero
measurements
4 (3.54) 1 (0.86) 5 (2.18)
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Analyses using multivariate linear regression adjusting for stratification factors (adjusted analysis and
principal analysis) and other confounding factors (fully adjusted analysis) were undertaken to assess the
robustness of conclusions based on these results (Table 7). It is clear from these analyses that there is no
evidence of any difference between the intervention groups in relation to work LSI, recorded at 24 weeks
post recovery. Taking account of stratification factors and the defined prognostic variables has no impact
on the results attained. Sensitivity analyses were also undertaken accounting for participants with zero
measurements (two-parts model), with individual missing HRET repetitions (simple imputation) and missing
entire HRET data sets (multiple imputation) and for compliance (CACE), and these showed that the results
were robust and, therefore, they had no impact on the interpretation of the results.
Post-estimation assessments of the fully adjusted primary outcome regression were carried out to ensure
that the results reported by the regression analyses were valid. There were no major issues identified
during these assessments and, therefore, the model was kept as simple as possible.
No formal subgroup analyses were carried out; however, results were explored visually using forest plots to
examine whether or not the effect of PRP compared with placebo was consistent across the stratification
factors (age group and trial site) and other prognostic variables (BMI categories, smoking status and sex)
(Figure 5). Although the variability was wide for some categories, such as trial site, as was expected owing
to the low number of participants randomised in some sites, the treatment effect was consistent across
subgroups, showing that the results are robust.
Analysis to address secondary outcomes
Overall Achilles tendon Total Rupture Score
An overall ATRS of 0 is the lowest (i.e. poorest) score a participant can attribute to their recovery and an
overall ATRS of 100 is the highest. At baseline, the unadjusted mean overall ATRS in the PRP group was
14.0, compared with 11.7 in the placebo group. By week 24, this had risen to 64.9 in the PRP group,
compared with 65.6 in the placebo group (Table 8).
A repeated-measures mixed-effects regression analysis accounting for the time elapsed since the intervention
was received was undertaken (see Table 8 and Figure 6). As with the primary outcome analysis, sensitivity
analyses were conducted to assess the robustness of conclusions based on these results. These analyses
found no evidence of any difference between the intervention groups in relation to average overall ATRS
recorded throughout the recovery period. Taking account of stratification factors had no impact on the
results attained. In addition, accounting for participants missing ATRS data (multiple imputation) and for
compliance (CACE) had no impact on the interpretation of the results. These analyses have shown that
participants’ overall ATRS increased from baseline to 24 weeks post treatment at an almost identical rate in
the PRP and the placebo groups, irrespective of adjustment for stratification variables.
Post-estimation assessments of the fully adjusted primary outcome regression were carried out to ensure
that the results reported by the regression analyses were valid. There were no major issues identified
during these assessments and, therefore, the model was kept as simple as possible.
As before, no formal subgroup analyses were carried out; however, results for the principal secondary
outcome (ATRS) were explored visually using forest plots to examine whether or not the effect of PRP
compared with placebo differed based on stratification factors (age group and trial site) and other
prognostic variables (BMI categories, smoking status and sex) (Figure 7).
As for the work LSI, this shows that the treatment effect was consistent across subgroups, showing that
the results are robust.
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TABLE 7 Primary outcome analysis on subjects with assessments for both legs (valid repetitions only), accounting for participants with true and potential zero measurements,






standard error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI
Unadjusteda
Primary analysis 201 34.925 29.528 to 40.321 38.292 32.922 to 43.661 –3.367 3.860 0.384 –10.979 to 4.246
Sensitivity: two-parts model 170 42.078 36.786 to 47.371 44.454 39.284 to 49.623 –2.375 3.747 0.527 –9.773 to 5.023
Sensitivity: simple imputation 201 34.930 29.536 to 40.325 38.299 32.931 to 43.667 –3.369 3.859 0.384 –10.979 to 4.241
Sensitivity: MICE 229 34.596 29.132 to 40.060 38.457 33.128 to 43.787 –3.861 3.897 0.323 –11.549 to 3.826
Sensitivity: CACE 201 34.551 28.599 to 40.502 38.292 32.988 to 43.595 –3.741 4.642 0.380 –12.095 to 4.614
Adjustedb
Primary analysis 201 34.671 30.945 to 38.397 38.543 33.753 to 43.333 –3.872 3.120 0.231 –10.454 to 2.710
Sensitivity: two-parts model 170 41.464 37.754 to 45.174 45.040 41.224 to 48.855 –3.576 2.741 0.209 –9.348 to 2.206
Sensitivity: simple imputation 201 34.676 30.946 to 38.407 38.551 33.768 to 43.334 –3.875 3.122 0.231 –10.462 to 2.712
Sensitivity: MICE 229 34.583 30.016 to 39.150 38.526 33.362 to 43.690 –3.943 3.312 0.256 –11.120 to 3.234
Sensitivity: CACE 201 34.235 30.242 to 38.228 38.548 34.241 to 42.854 –4.313 3.413 0.206 –11.003 to 2.377
Fully adjustedc
Primary analysis 201 34.360 30.438 to 38.282 38.851 34.161 to 43.541 –4.491 3.249 0.185 –11.345 to 2.364
Sensitivity: two-parts model 170 41.614 37.552 to 45.675 44.897 41.177 to 48.617 –3.283 2.886 0.271 –9.372 to 2.805
Sensitivity: simple imputation 201 34.365 30.438 to 38.293 38.859 34.176 to 43.541 –4.493 3.254 0.185 –11.358 to 2.371
Sensitivity: MICE 229 34.378 29.740 to 39.017 38.594 33.361 to 43.827 –4.216 3.400 0.237 –11.572 to 3.140
Sensitivity: CACE 201 33.862 29.725 to 37.999 38.850 34.673 to 43.027 –4.988 3.515 0.156 –11.877 to 1.901
MICE, multivariate imputation by chained equations.
a LSI and treatment group.
b LSI, treatment group and age category, clustered by trial site.


















Pain-related Achilles tendon Total Rupture Score
Participants’ pain-related ATRSs, a subset of the overall ATRS, increased at a relatively steady rate from
baseline to 24 weeks post treatment, with similar rates in the PRP and placebo groups, irrespective of
adjusting for stratification variables (Table 9 and Figure 8).
Patient-specific functional scale
Participants’ overall PSFS score increased from baseline to 24 weeks post treatment at an almost identical rate
in the PRP and placebo groups, irrespective of adjusting for stratification variables (Table 10 and Figure 9).
Maximum concentric displacement and maximum number of repetitions
As with the primary outcome analysis, there was no difference between the intervention groups in the
maximum concentric displacement LSI achieved and the maximum number of repetitions achieved (Table 11).
After adjusting for all stratification variables, the average maximum concentric displacement LSI [the LSI
calculated as (maximum displacement in the injured leg/maximum displacement in the uninjured leg) × 100,
to account for potential ability differences] achieved by participants in the PRP group was 55.1 (95% CI 51.4
to 58.8), compared with 55.4 (95% CI 49.6 to 61.3) in the placebo group. This difference was not significant
(mean difference –0.3, 95% CI –6.1 to 5.4; p = 0.898). Similarly, after adjusting for stratification variables,
Subgroups Numbersa
















Smoking status, heterogeneity (p = 0.386)
Sex, heterogeneity (p = 0.219)







































Effect size (95% Cl)
–2.39 (–10.71 to 5.93)
–8.75 (–23.83 to 6.33)
–6.12 (–18.71 to 6.48)
5.53 (–6.07 to 17.13)
5.72 (–17.74 to 29.17)
2.64 (–11.63 to 16.91)
–7.34 (–16.94 to 2.26)
–0.60 (–9.33 to 8.12)
–11.84 (–27.45 to 3.76)
–17.38 (–44.68 to 9.91)
–7.10 (–36.58 to 22.39)
–1.10 (–33.07 to 30.86)
–8.30 (–42.82 to 26.23)
–15.17 (–69.76 to 39.42)
–15.72 (–43.01 to 11.58)
–27.25 (–60.31 to 5.80)
7.94 (–28.68 to 44.56)
–29.74 (–96.60 to 37.12)
–35.31 (–96.34 to 25.73)
–14.58 (–54.44 to 25.29)
–30.97 (–108.17 to 46.23)
36.99 (–4.70 to 78.69)
27.22 (–14.47 to 68.91)
3.05 (–14.90 to 21.01)
3.45 (–14.36 to 21.26)
–15.76 (–30.39 to 1.12)
Favours placebo injection Favours PRP injection
FIGURE 5 Forest plot of work LSI effect demonstrating the effect of the intervention on subgroups of defined
stratification and prognostic factors. a, Number in the placebo arm vs. number in the PRP arm. The Cardiff and Royal
Devon and Exeter sites were excluded as neither had patients in the treatment arm completing HRET assessment.
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standard error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI
Baseline
Adjusted analysis 216 14.090 10.974 to 17.205 11.668 8.637 to 14.699 2.422 2.218 0.275 –1.925 to 6.769
Sensitivity: HRET mITT 201 14.082 10.904 to 17.260 11.309 8.192 to 14.426 2.773 2.273 0.222 –1.682 to 7.227
Sensitivity: MICE 229 14.899 11.566 to 18.232 13.085 9.781 to 16.389 –1.814 2.401 0.450 –2.892 to 6.723
Sensitivity: CACE 216 14.480 12.139 to 16.821 11.918 9.789 to 14.047 2.562 1.534 0.095 –0.446 to 5.569
Week 4
Adjusted analysis 216 28.461 25.286 to 31.637 30.609 27.561 to 33.657 –2.148 2.246 0.339 –6.550 to 2.255
Sensitivity: HRET mITT 201 28.441 25.212 to 31.670 31.304 28.168 to 34.441 –2.864 2.298 0.213 –7.369 to 1.641
Sensitivity: MICE 229 28.849 27.688 to 34.498 31.093 27.688 to 34.498 –2.244 2.476 0.365 –7.098 to 2.609
Sensitivity: CACE 216 28.175 24.881 to 31.469 30.499 27.527 to 33.471 –2.325 2.177 0.286 –6.591 to 1.942
Week 7
Primary analysis 216 37.579 34.432 to 40.727 38.619 35.537 to 41.702 –1.040 2.248 0.644 –5.446 to 3.366
Sensitivity: HRET mITT 201 37.369 34.170 to 40.568 38.381 35.207 to 41.555 –1.012 2.301 0.660 –5.521 to 3.497
Sensitivity: MICE 229 37.454 34.014 to 40.894 38.523 35.083 to 41.962 –1.069 2.490 0.668 –5.951 to 3.813























standard error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI
Week 13
Primary analysis 216 51.663 48.483 to 54.844 53.114 50.016 to 56.213 –1.451 2.266 0.522 –5.892 to 2.990
Sensitivity: HRET mITT 201 53.091 49.858 to 56.324 53.432 50.254 to 56.611 –0.342 2.315 0.883 –4.878 to 4.195
Sensitivity: MICE 229 50.344 46.846 to 53.842 51.656 48.135 to 55.178 –1.312 2.498 0.599 –6.210
Sensitivity: CACE 216 51.635 47.801 to 55.468 53.236 49.855 to 56.618 –1.601 2.723 0.557 –6.939 to 3.736
Week 24
Primary analysis 216 64.987 61.864 to 68.111 65.530 62.495 to 68.565 –0.543 2.222 0.807 –4.899 to 3.813
Sensitivity: HRET mITT 201 66.321 63.135 to 69.507 65.815 62.694 to 68.936 0.506 2.277 0.824 –3.956 to 4.968
Sensitivity: MICE 229 62.697 59.303 to 66.092 63.890 60.520 to 67.261 –1.193 2.434 0.624 –5.963 to 3.577
Sensitivity: CACE 216 65.143 60.681 to 69.604 65.738 61.769 to 69.708 –0.595 3.013 0.843 –6.500 to 5.310





































































































































































































FIGURE 6 The ATRS principal adjusted repeated-measures mixed-effects regression model demonstrating the
change in ATRS in PRP and placebo group participants over time. 0 = totally limited because of ATR; 100 = not
limited at all because of ATR.
Subgroups Numbersa




















Sex, heterogeneity (p = 0.440)
Male
Female 32 vs. 22
–74 0 74
Effect size (95% Cl)
–0.73 (–7.02 to 5.56)
–4.23 (–15.13 to 6.68)
–1.71 (–11.14 to 7.72)
–0.46 (–8.93 to 8.02)
5.38 (–11.07 to 21.82)
–2.66 (–12.99 to 7.67)
–2.54 (–9.58 to 4.51)
–0.35 (–6.65 to 5.95)
–5.38 (–16.48 to 5.71)
–5.61 (–25.21 to 13.99)
0.68 (–19.64 to 21.01)
–1.50 (–23.94 to 20.94)
4.60 (–20.91 to 30.11)
–2.67 (–39.48 to 34.15)
–13.00 (–33.16 to 7.16)
–8.17 (–31.45 to 15.12)
–15.60 (–41.11 to 9.91)
–0.00 (–49.39 to 49.39)
–8.20 (–37.65 to 21.25)
–17.73 (–47.19 to 11.72)
17.00 (–40.03 to 74.03)
14.00 (–16.80 to 44.80)
11.17 (–19.64 to 41.97)
2.12 (–10.80 to 15.04)
1.45 (–11.15 to 14.05)
–3.71 (–14.23 to 6.81)

































Favours placebo injection Favours PRP injection
FIGURE 7 Forest plot of ATRS demonstrating the effect of the intervention on overall ATRS in subgroups of defined
stratification and prognostic factors. a, Number in the placebo arm vs. number in the PRP arm. The Cardiff and Royal
Devon and Exeter sites were excluded as neither had patients in the treatment arm completing the assessment.
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TABLE 9 Adjusted secondary outcome analysis results for pain-related ATRS reported by participants over time
Time point n




error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI




0.628 0.395 0.112 –0.146 to
1.401




–0.023 0.400 0.954 –0.806 to
0.761




0.327 0.401 0.415 –0.459 to
1.113




0.255 0.405 0.529 –0.538 to
1.048




0.212 0.395 0.592 –0.563 to
0.987
Adjusted for ATRS, treatment group, study site and age category, with time elapsed included as a random effect.






























FIGURE 8 The ATRS pain mixed-effect regression model. Results from the adjusted repeated-measures mixed-effects
regression model demonstrating the change in ATRS pain measure in PRP and placebo group participants over time.
0 = totally limited because of pain; 10 = not limited at all because of pain.
TABLE 10 Adjusted secondary outcome analysis results for PSFS reported by participants over time
Time point n




error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI




–0.013 0.291 0.965 –0.583 to
0.557




–0.009 0.293 0.975 –0.583 to
0.564




–0.229 0.293 0.435 –0.804 to
0.346




0.034 0.296 0.909 –0.546 to
0.614




–0.297 0.291 0.308 –0.868 to
0.274
Adjusted for PSFS, treatment group, study site and age category, with time elapsed included as a random effect.
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the average maximum number of repetitions proportion [calculated as (maximum number of repetitions in
the injured leg/maximum number of repetitions in the uninjured leg) × 100, to account for potential ability
differences] achieved by participants in the PRP group was 50.1% (95% CI 43.7% to 56.4%), compared
with 60.7% (95% CI 52.8% to 68.7%) in the placebo group. This difference was not statistically significant
(mean difference –10.7, 95% CI –21.9 to 0.6; p = 0.061).
Visual analogue scale
Participants’ pain levels as recorded in their pain diaries in the first 2 weeks post intervention demonstrate that
the pain experienced by participants decreased at a relatively steady rate from day 1 to day 14 (Figure 10).
Accounting for the stratification factors, participants in the PRP group reported a mean overall VAS score of
37.3 (95% CI 33.0 to 41.7) at day 1, with the placebo group reporting a similar level of 31.2 (95% CI 26.7
to 35.7). By day 14, participants in the PRP group were reporting a mean VAS score of 9.5 (95% CI 5.2 to
13.9) and participants in the placebo group were reporting a mean VAS score of 13.6 (95% CI 9.0 to 18.1).
This difference at day 14 was not significant (mean difference –4.0, 95% CI –10.3 to 2.3; p = 0.210). This
demonstrates that the decline in reported pain was at similar rates in the PRP and placebo groups.
Short Form questionnaire-12 items quality of life
Participants’ SF-12 physical component scores (PCSs) increased gradually over time to near-normal levels at
24 weeks post treatment (Figure 11) at an almost identical rate in the PRP and placebo groups, irrespective
of stratification variable and accounting for participants’ pre-injury PCSs (Table 12).






























FIGURE 9 The PSFS mixed-effects regression model. Results from the adjusted repeated-measures mixed-effects
regression model demonstrating the change in PSFS in PRP and placebo group participants over time. 0 = unable
to carry out activities; 10 = able to carry out activities at same levels as before ATR.
TABLE 11 Adjusted analysis results for maximum displacement LSI and maximum number of repetitions proportion
achieved by participants during their HRET, on subjects with assessments for both legs (valid repetitions only),
accounting for participants with true and potential zero measurements
HRET
measure n





error p-value 95% CI
PRP Placebo
Average 95% CI Average 95% CI
Maximum
displacement













–10.671 5.325 0.061 –21.906
to 0.564
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FIGURE 11 The SF-12 PCS mixed-effects regression model. Results from the adjusted repeated-measures mixed-effects
regression model demonstrating the change in PCS in PRP and placebo group participants over time, with mean































FIGURE 10 Pain VAS mixed-effects regression model. Results from the adjusted repeated-measures mixed-effects
regression model demonstrating the change in VAS pain measure in PRP and placebo group participants in the first
2 weeks post intervention. 0 = no pain; 100 = severe pain.
TABLE 12 Adjusted secondary outcome analysis results for SF-12 PCS reported by participants over time
Time
point n




error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI
Baseline:
post injury
213 30.720 29.250 to
32.191
29.799 28.367 to 31.230 0.922 1.048 0.379 –1.133 to
2.976
Week 4 213 38.865 37.376 to
40.354
39.001 37.565 to 40.438 –0.136 1.057 0.897 –2.208 to
1.935
Week 7 213 40.731 39.249 to
42.214
42.422 40.971 to 43.872 –1.691 1.059 0.110 –3.767 to
0.386
Week 13 213 45.760 44.260 to
47.259
46.272 44.812 to 47.731 –0.512 1.069 0.632 –2.606 to
1.584
Week 24 213 50.240 48.751 to
51.729
49.436 47.996 50.876 0.805 1.058 0.447 –1.269 to
2.879
Adjusted for PCS, treatment group, study site, age category and PCS pre-injury score, with time elapsed included as a
random effect.
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Participants’ SF-12 mental component scores (MCSs) remained relatively stable and close to their pre-injury
scores over the entire trial follow-up period (Figure 12). At 24 weeks post treatment, participants in the
PRP group had a MCS that was nearly 3 points lower than that of the MCS in the placebo group after
adjusting for stratification variables and accounting for participants’ pre-injury MCSs (p = 0.035) (Table 13).
Success of blinding
Participants were questioned following their 24-week HRET assessment as to which treatment they
believed they received; 210 participants responded to this question (Table 14).
Using participant responses to this question, assessments of blinding were carried using the James et al.69
and Bang et al.70 blinding indices to determine whether or not participants were successfully blinded to the
intervention they received. Using the information generated from both of these assessments, we can be
confident that there is no evidence to suggest that blinding in this trial was unsuccessful. For further details
on the outcome of these assessments, see Appendix 3.























FIGURE 12 The SF-12 MCS mixed-effects regression model. Results from the adjusted repeated-measures mixed-effects
regression model demonstrating the change in MCS in PRP and placebo group participants over time.
TABLE 13 Adjusted secondary outcome analysis results for SF-12 MCS reported by participants over time
Time
point n




error p-value 95% CI
PRP Placebo
Mean 95% CI Mean 95% CI
Baseline:
post injury




–1.303 1.281 0.309 –3.813 to
1.207




–2.398 1.295 0.064 –4.936 to
0.139




–1.365 1.299 0.293 –3.911 to
1.180




0.742 1.308 0.571 –1.822 to
3.305




–2.714 1.289 0.035 –5.242 to
–0.187
Adjusted for MCS, treatment group, study site, age category and MCS pre-injury score, with time elapsed included as a
random effect.
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Adverse events
Adverse events are reported in Table 15. Only one participant (1/229, 0.4%) reported a SAE during the
study. There were similar AE rates in the treatment groups [PRP, 84/113 (74%); placebo, 90/116 (78%)].
TABLE 14 Participant prediction of treatment received, by intervention group
Participant prediction of treatment
Intervention group, n (%)
Total, n (%)PRP Placebo
PRP injection 32 (30.77) 28 (26.41) 60 (28.57)
Imitation injection 17 (16.35) 9 (8.49) 26 (12.38)
Don’t know 55 (52.88) 69 (65.09) 124 (59.05)
Total 104 (100.00) 106 (100.00) 210 (100.00)
TABLE 15 Complications reported by participants during the 24 weeks after injury and treatment
Complication type
Intervention group, n (%)
PRP (N= 113) Placebo (N= 116)
Participants experiencing at least one AE of any typea 84 (74.34) 90 (77.59)
SAEsa 1 (0.88) 0
ST elevation myocardial infarction 1 (0.88) 0
AEsa 84 (74.34) 90 (77.59)
Foreseeable AEsa 83 (73.45) 87 (75.00)
Mild discomfort or minor bleeding following injection 22 (19.47) 8 (6.90)
Technical complications of lower leg casting and splinting 38 (33.63) 28 (24.14)
Consequences of depending on walking aids 1 (0.88) 1 (0.86)
Syncopal episode related to venesection or tendon injection 0 0
Discomfort at rupture site during rehabilitation 9 (7.96) 10 (8.62)
Swelling or bruising of the lower leg and foot 68 (60.18) 77 (66.38)
DVT in a lower limb 6 (5.31) 5 (4.31)
Re-rupture of treated Achilles tendon 6 (5.31) 4 (3.45)
Unforeseeable AEsa 16 (14.16) 19 (16.38)
Serious infection of injection site of ATR 0 0
Skin breakdown or ulceration of treated lower leg 13 (11.50) 13 (11.21)
Severe pain (more than simple analgesia) > 10 days after injection 6 (5.31) 6 (5.17)
Other AEs related to treatment or ATRa 13 (11.50) 13 (11.21)
Frequent discomfort at injection site 5 (4.42) 6 (5.17)
Infection at injection site confirmed by doctor 0 3 (2.59)
Infection at non-injection siteb 0 3 (2.59)
Other problemc 9 (7.96) 6 (5.17)
a Participants could have experienced multiple AEs so number of participants reporting foreseeable and unforeseeable AEs
may not add up to the overall total reporting.
b Infections included cellulitis, pneumonia, and an infected insect bite on the treated leg.
c Participant-specific complications associated with treatment or rupture not covered by other complication types.
Note
Reproduced from Keene et al.75 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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The overall re-rupture rate among study participants was 4.4% (10/229), with similar rates in the PRP group
(6/113, 5.3%) and the placebo group (4/116, 3.5%). Nine of the ten participants with a re-rupture were then
treated with surgery. DVT rates were also similar (PRP group: 6/113, 5.3%; placebo group: 5/116, 4.3%).
There were some complications at the injection site, with 11 out of 229 (5%) participants reporting
frequent discomfort and 3 out of 229 (1%) participants reporting clinically diagnosed infections. However,
no clinically serious infections were reported.
Summary of key findings
l The results of the analyses of the primary end point allow us to conclude that there was no evidence of
a difference between PRP injection and placebo for the treatment of acute ATR in adults in terms of
muscle–tendon function at 24 weeks.
l There was no evidence of any differences between the intervention groups in the PROMs (ATRS, PSFS,
pain and SF-12 physical function) across all time points assessed. There was a small statistically
significant difference in SF-12 mental function, with the PRP group doing worse than the placebo
group. This was probably due to chance.
l There was no difference in complications and AEs between the two groups.
l The results were robust to adjustment for stratification factors (age and centre) with/without other
confounding factors and for the sensitivity analyses.
l The overall re-rupture rate was low, at 4.37%, and no significant difference was seen between
the groups.
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Chapter 4 Substudy 1: platelet-rich plasma and
blood analysis
Introduction
Autologous platelet preparations are increasingly being used in many areas of regenerative medicine.
However, there are few properly controlled RCTs and the preparation, content and definitions of many
platelet preparations are generally poorly defined, standardised and controlled. Most platelet products
therefore have varying concentrations of blood cells [platelets, white blood cells (leucocytes) and red blood
cells (erythrocytes)], plasma and fibrin. Studying the potential role(s) of all the cells and their bioactive
factors is, therefore, essential to understand the variables associated with the biological activity and efficacy
of any platelet preparation.
Although our pilot study demonstrated efficacy signal of a PRP (L-PRP) preparation in ATR healing, as a pilot
study it was underpowered to study the variables within PRP preparations that may be associated with
efficacy of healing. The PATH-2 trial, powered on the work LSI as the primary outcome, randomised a total
of 230 participants, 103 of whom received the PRP product. This provided the opportunity to not only study
the variation in cellular and bioactive components within the PRP but also to determine the reliability of
using a single device to prepare an autologous sterile product for ATR healing across 19 trial centres.
The aim of substudy 1 was to determine the cellular content of the PRP product (platelets, erythrocytes and
leucocytes) and the quality and growth factor content of the PRP preparations used. This provided one of the
most comprehensive studies of the within- and between-centre performance of a single preparation device
of PRP in a clinical trial setting. The data also provided insight into the key variables within PRP that were
associated with the biological efficacy of the product as determined by the primary and secondary outcomes.
Methods
Blood and platelet-rich plasma samples
Venous blood (1–5 ml) was taken from all participants recruited into the trial and anticoagulated within
ethylenediaminetetraacetic acid vacutainers (Becton, Dickinson and Company, Plymouth, UK). In the PRP
treatment group, an additional 50 ml of venous blood was taken for automated sterile PRP preparation in
the centrifuge; 8 ml of sterile PRP was then harvested and 4 ml was used for injection into the Achilles
tendon, and the remaining 4 ml was divided into four 1-ml aliquots. One microtube was immediately
frozen at –70 °C for storage until the end of the trial when it was used for batch measurement of growth
factor levels (see below). The remaining PRP aliquots (each 1 ml) were stimulated at room temperature for
5 minutes by addition to two tubes (Platelet Solutions Ltd, Nottingham, UK) containing either (tube B) saline
alone, to provide an unstimulated baseline, or (tube C) adenosine diphosphate and U46619, to fully activate
the platelets. Both samples were then fixed using 1 ml of PAMFix (Platelet Solutions Ltd, Nottingham, UK).
The whole blood, unfixed PRP and tubes B and C were then transported at room temperature by courier to
the Institute of Inflammation and Ageing at the University of Birmingham and processed as soon as possible
on arrival.
Cell counting
Whole-blood and unfixed PRP cell counts were conducted using the Sysmex XN-1000 haematology analyser
(Sysmex UK, Milton Keynes, UK). The analyser utilises three primary analysis principles: fluorescence flow
cytometry, direct current detection with hydrodynamic focusing and sodium lauryl sulfate haemoglobin
detection. The WNR (white cell nucleated) channel evaluates white blood cell count, basophils and nucleated
DOI: 10.3310/eme06120 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 12
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Alsousou et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
red blood cells. An impedance red blood cell count is also reported. The WDF (white blood cell differential)
channel also provides a differential count of the neutrophils, lymphocytes, eosinophils, monocytes and
immature granulocytes. The platelet fluorescence (PLT-F) channel is a specialised fluorescence optical analysis
exclusively for platelets. The PLT-F parameter utilises traditional fluorescence flow cytometry in which
platelets are stained with oxazine (a ribonucleic acid binding dye that eliminates any interference mediated
by cellular debris). A measurement of platelet production (immature platelet fraction) is also in this channel.
The analyser thus reports three platelet counts (platelet impedance, platelet optical and PLT-F), mean platelet
volume and the immature platelet fraction. Quality control material (XN Check™, Sysmex UK, Milton Keynes,
UK) was tested on a daily basis to ensure instrument performance throughout the trial. The instrument
was also enrolled in a national external quality assurance scheme (UK NEQAS, Watford, UK) and maintained
on a service contract (Sysmex UK). To determine normal ranges for each cellular parameter, blood samples
from 40 healthy volunteers (control cohort) were analysed and normal ranges are represented as the mean
value ± 2 SDs.
Measurement of platelet quality
Tubes B and C containing fixed resting and activated platelets, respectively, were analysed for the
expression of a platelet-specific activation marker P-selectin (CD62P) by flow cytometry as a measure
of platelet quality. After gentle mixing, 5 µl of fixed PRP from tubes B and C was incubated with 5 µl of
test antibody [CD62P conjugated to flourescein isothiocyanate (FITC); Beckman Coulter Inc., Brea, CA, USA]
or its corresponding isotype control (IgG conjugated to FITC; Beckman Coulter Inc.) with 40 µl of 0.2-µm
filtered phosphate buffered saline (pH 7.4) for 20 minutes at room temperature. The samples were then
further diluted by the addition of 4 ml of phosphate-buffered saline. The platelets were then analysed by
flow cytometry (Accuri™ Flow cytometer, Becton, Dickinson and Company). Platelets were identified
according to their characteristic size and granularity (using log-forward scatter and log-side scatter), with a
forward-scatter threshold of 25,000 to eliminate noise. An amorphous gate was placed around the platelet
population and 10,000 events were collected. Analysis regions were set using the isotype control so that
0.5% of the platelet population was positive. CD62P positivity was then measured and both percentage
expression and median fluorescent intensity of all platelet events were recorded.
Measurement of growth factor levels within platelet-rich plasma
At the end of participant recruitment, all frozen aliquots of PRP were shipped to Birmingham for analysis
of growth factor levels. Appropriate batches of samples were thawed at 37 °C for 10 minutes. One-fortieth
volume of 20% Triton™ X-100 (Roche Diagnostics, Mannhein, Germany) was added to ensure full lysis
prior to a further incubation at 37 °C for 10 minutes. Samples were mixed then centrifuged at 1500 g for
10 minutes at room temperature. Supernatants were then removed and simultaneously assayed for five
different growth factors (TGF-β1, FGF, VEGF, IGF-1 and PDGF-AB) by commercial enzyme-linked immunosorbent
assay (ELISA) kits (Bio-Techne Ltd, Abingdon, UK). Optimal sample dilutions for each growth factor were
predetermined by assaying L-PRP samples prepared from control volunteers using the identical method
of preparation as in the trial. Diluted samples, blanks and standards were pipetted in duplicate into 96 well
plates coated with capture antibodies and incubated as instructed within each growth factor ELISA kit.
Plates were then washed four times with the washing buffers provided and the peroxidase-conjugated
secondary antibodies provided within each kit were added to each well and incubated as instructed. Plates
were then washed four times with washing buffer before addition of substrate solution to each well. The
plates were then incubated for 20–30 minutes at room temperature in the dark before the addition of the
stop solution. The optical density of each well was then measured immediately using a microplate reader
and readings taken at 450 nm. A further reading was taken at 540 nm and the values subtracted from the
readings at 450 nm to correct for optical imperfections in the plate. The duplicate readings were averaged
for each standard, control and sample, and the zero standard optical density was subtracted. Standard
curves were generated by plotting the mean absorbance for each standard on the y-axis against the
concentration on the x-axis and the best-fit line generated by regression analysis. Unknown sample values
were then read off the regression line and final concentrations were determined by multiplying using the
dilution factors used in each assay. The concentration for each growth factor per ml of lysate was reported.
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Statistical analysis
The comparability of key blood parameters and bioactive factors for each treatment group was
summarised with means and SDs. For whole-blood parameters, a Student’s t-test was used to explore
differences between treatment arms.
Correlation between the primary outcome and both key blood parameters and bioactive factors was
explored using Pearson’s correlation.
As per analyses in the main study, a p-value of < 0.05 was seen as indicative of a statistically significant
difference.
Results
Cell counts within whole blood and platelet-rich plasma
Summary statistics for key blood parameters in whole-blood and PRP samples are given in Table 16. A
comparison of the whole-blood counts in the PRP and placebo groups is shown in Figure 13. There was no
significant difference in the whole-blood samples between the treatment groups for red blood cell count
(mean difference –0.002, 95% CI –0.144 to 0.139; p = 0.974), white blood cell count (mean difference
–0.259, 95% CI –0.784 to 0.264; p = 0.330) or platelet count (as PLT-F) (mean difference –19.045, 95% CI
–38.310 to 0.040; p = 0.051). Figure 14 illustrates the cell counts within the PRP samples showing the
TABLE 16 Summary statistics for key blood parameters in whole-blood and PRP samples, by intervention group
Parameter
Intervention group
Total (N= 229)PRP (N= 113) Placebo (N= 116)
n Mean SD n Mean SD n Mean SD
Whole-blood
Erythrocytes (1012/l) 107 4.825 0.589 114 4.827 0.475 221 4.826 0.532
Leucocytes (109/l) 107 6.742 2.049 114 7.001 1.904 221 6.875 1.975
Platelets (109/l)a 104 208.183 77.729 110 227.227 63.537 214 217.972 71.264
PRP
Erythrocytes (1012/l) 101 0.907 1.489 – – – – – –
Leucocytes (109/l) 101 15.130 10.275 – – – – – –
Platelets (109/l)a 98 852.551 438.958 – – – – – –
IGF-1 (ng/ml) 103 78.178 23.180 – – – – – –
TGF-β1 (ng/ml)b 97 131.915 74.372 – – – – – –
PDGF-AB (ng/ml)c 100 55.339 27.640 – – – – – –
VEGF (ng/ml)d 103 0.981 0.721 – – – – – –
bFGF (pg/ml)e,f 103 111.038 76.970 – – – – – –
bFGF, basic fibroblast growth factor.
a Using PLT-F measure.
b Participants with a value of < 10.02 ng/ml (n = 2) included in data as 0 ng/ml.
c Participants with a value of < 5.1 ng/ml (n = 3) included in data as 0 ng/ml.
d Participants with a value of < 0.125 ng/ml (n = 2) included in data as 0 ng/ml.
e Participants with a value of < 10 pg/ml (n = 3) included in data with as 0 pg/ml.
f Participants with a value of < 20 pg/ml (n = 3) included in data as 10 pg/ml.
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variation in platelet, red blood cell and white blood cell counts, with the whole-blood sample summaries
given in the same figure for reference. The mean platelet count (PLT-F) in the PRP sample was 852.5 ×
109/l, but with a wide range (6.0–2903.0 × 109/l). Although a small number of PRP platelet counts were
lower than original whole-blood counts due to some unforeseen centrifuge problems, the overall mean
increase in platelets was 4.1-fold. The mean red blood cell count was 0.9 × 1012/l (range 0.1–9.0 × 1012/l).
As expected, the red blood cell count decreased on average in the PRP by a factor of 5.3 of the original






















































































FIGURE 13 Cell counts in whole-blood samples, by intervention group. (a) Erythrocytes; (b) leucocytes; and
(c) platelets. a, Using the PLT-F measure.
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As this preparation is a L-PRP, the mean white blood cell count increased by a factor of 2.2, as expected.
The white blood cell differential count was 14.6% monocytes (mean 2.2 × 109/l, range 0–21.1 × 109/l),
45.2% lymphocytes (mean 6.8 × 109/l, range 0.1–18.7 × 109/l), 39.2% neutrophils (mean 5.9 × 109/l,
range 0.2–30.4 × 109/l), 0.1% basophils (mean 0.02 × 109/l, range 0–0.5 × 109/l) and 0.82% eosinophils
(mean 0.1 × 109/l, range 0–1.5 × 109/l).


















































































FIGURE 14 Cell counts in PRP samples, represented against counts in whole-blood samples. (a) Erythrocytes;
(b) leucocytes; and (c) platelets. a, Using the PLT-F measure.
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Platelet quality
The basal levels of CD62P expression [percentage and mean fluorescence intensity (MFI)] within the
platelets of resting basal PRP and activated PRP samples are shown in Table 17 and Figure 15. In resting
PRP, the mean CD62P expression was 4.3% with a MFI of 248.6. The majority of PRP samples were
therefore of good quality with low levels of activation, with a few exceptions. In the activated PRP samples,
the mean CD62P expression was 60.1% with a MFI of 1208.0. The majority of PRP samples were functional,
with the majority of platelets in the PRP preparations being shown to be capable of activation and
degranulation, with a few exceptions.
TABLE 17 Summary statistics for key blood parameters in PRP samples
Parameter
PRP samples
Activated (N= 103) Resting (N= 103)
n Mean SD n Mean SD
CD62P expression (%) 102 60.092 22.264 103 4.274 5.046







































FIGURE 15 Platelet quality in PRP samples, demonstrating both (a) CD62P expression and (b) MFI in activated and
resting (unactivated) PRP.
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Growth factor levels within platelet-rich plasma
The levels of each growth factor are shown in Table 16 and Figure 16.
Blood and platelet-rich plasma variables and clinical outcomes
Baseline blood and the primary outcome measure
Parameters of baseline whole blood taken before the intervention did not correlate with the primary
outcome measure at 24 weeks (Figure 17 and Table 18), irrespective of intervention group.
Platelet-rich plasma and the primary outcome measure
The PRP cell count and growth factor concentration correlation with the primary outcome measure were
analysed to assess if the variability in PRP had any effect on the outcome. The results are displayed in
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FIGURE 17 Correlation between whole-blood sample blood cell counts and the primary outcome (work LSI) at
24 weeks. (a) Erythrocytes; (b) leucocytes; and (c) platelets. a, Using the PLT-F measure. (continued )
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FIGURE 17 Correlation between whole-blood sample blood cell counts and the primary outcome (work LSI) at
24 weeks. (a) Erythrocytes; (b) leucocytes; and (c) platelets. a, Using the PLT-F measure.
TABLE 18 Results from primary outcome correlation assessments overall and by intervention group, for whole-blood
sample key blood parameters
Parameter by group n r % variancea p-value
Erythrocytes
PRP 97 0.133 1.780 0.193
Placebo 99 0.122 1.496 0.228
Leucocytes
PRP 97 –0.184 3.393 0.071
Placebo 99 –0.172 2.976 0.088
Plateletsb
PRP 94 –0.153 2.329 0.142
Placebo 96 –0.080 0.634 0.440
r, Pearson’s product-moment correlation coefficient.
a Proportion of variance in LSI explained by key blood parameter, calculated as (R2 × 100).
b As PLT-F.
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FIGURE 18 Correlation between PRP sample blood cell counts and the primary outcome (work LSI) at 24 weeks.
(a) Erythrocytes; (b) leucocytes; and (c) platelets. a, Using the PLT-F measure.
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FIGURE 19 Correlation between platelet quality and the primary outcome (work LSI) at 24 weeks. (a) Activated













FIGURE 20 Correlation between growth factors and the primary outcome (work LSI) at 24 weeks. (a) IGF-1;
(b) TGF-β1; (c) PDGF-AB; (d) VEGF; and (e) bFGF. bFGF, basic fibroblast growth factor. (continued )
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FIGURE 20 Correlation between growth factors and the primary outcome (work LSI) at 24 weeks. (a) IGF-1;
(b) TGF-β1; (c) PDGF-AB; (d) VEGF; and (e) bFGF. bFGF, basic fibroblast growth factor. (continued )
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The red blood cell, white blood cell and platelet (as PLT-F) counts and work LSI at 24 weeks linear regression
analysis showed no significant correlation (see Figure 18). This was also the case for the platelet-quality
measures of interest (see Figure 19) and for all growth factors (see Figure 20) with the exception of VEGF,
for which the evidence suggests a negative correlation between PRP VEGF concentration and week 24
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FIGURE 20 Correlation between growth factors and the primary outcome (work LSI) at 24 weeks. (a) IGF-1;
(b) TGF-β1; (c) PDGF-AB; (d) VEGF; and (e) bFGF. bFGF, basic fibroblast growth factor.
TABLE 19 Results from primary outcome correlation assessments overall and by intervention group, for PRP sample
key blood parameters
Parameter n r % variancea p-value
Blood cell counts
Erythrocytes 91 0.126 1.590 0.234
Leucocytes 91 –0.103 1.053 0.333
Plateletsb 88 0.128 1.649 0.233
Platelet quality
Activated CD62P expression (%) 92 0.038 0.142 0.721
MFI 92 –0.004 0.002 0.966
Growth factors
IGF-1 93 0.124 1.248 0.287
TGF-β1 88 0.005 0.003 0.960
PDGF-AB 90 < 0.001 < 0.001 0.998
VEGF 93 –0.231 5.355 0.026
bFGF 93 –0.102 1.049 0.329
bFGF, basic fibroblast growth factor; r, Pearson’s product-moment correlation coefficient.
a Proportion of variance in LSI explained by key blood parameter, calculated as (R2 × 100).
b As PLT-F.
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Discussion
The results showed that the whole-blood parameters in participants’ venous blood samples were identical
in both groups immediately prior to injection of PRP or placebo. As it is possible that variation in platelets
and leucocytes in whole blood may play a role in the healing process of tendons, these results confirmed
that there was no baseline blood variation between the groups.
To our knowledge, this is the largest analysis of PRP in a multicentre RCT in a musculoskeletal disease
or injury setting. The results of this substudy showed that the centrifuging method in this population
produced L-PRP. The average platelet count in PRP was > 4 times that in whole blood. The leucocyte
concentration was 2.2 times the whole-blood leucocyte concentration. This may have an influence on the
healing process as both cells play a crucial role in the initial tissue response to an injury.
The growth factors IGF-1, TGF-β1, PDGF-AB and VEGF are reportedly the greatest contributors to tissue
healing in PRP. Previous work has identified a need for growth factor analysis so that the interpatient
variation in different parameters can be properly explored. Here, the results of such an analysis on 103
samples are presented. The hypothesis that there would be a significant positive relationship between
growth factor concentrations and platelet and leucocyte concentrations was mostly supported in this
study. Most of the growth factors had a significant or moderate association with platelet concentrations.
The lack of association with IGF-1 supports the opinion that platelets are not the major contributors of
that factor.
An important finding of the growth factors analysis was the large degree of variation exhibited between
participants, even when corrected for platelet concentration. Using correlation and regression analysis,
statistically significant associations have been identified between the concentrations of TGF-β1, PDGF-AB,
VEGF, basic fibroblast growth factor (bFGF), platelets and leucocytes. These relationships may contextualise
the understanding of the biological mechanisms at work in PRP tissue response.
The relationship between product-variable biological content and clinical effect was presented. The key
finding was that there was no association of either the cellular or growth factors’ content with the primary
outcome measure. The level of platelet activation as a measure of platelet quality at baseline also did not
correlate with the clinical outcome. Baseline blood was also assessed to make sure that there was no
variation between the two groups. There was no correlation of the cellular component of whole blood on
the primary outcome.
The results of substudy 1 confirm that variability in this biological product did not change the outcome of
Achilles tendon injury management.
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Chapter 5 Substudy 2: immunohistochemistry
study of needle biopsies from Achilles tendon rupture
lesion site
Introduction
Torn and healing tendons progress through stages of scar tissue formation and remodelling, in which
processes of cell death, inflammation, matrix breakdown, stem cell migration, proliferation, revascularisation,
tenocyte differentiation, matrix synthesis and matrix remodelling are evident.76,77 Although increased
cellularity and vascular invasion are essential features of initial scar tissue formation, successful remodelling
requires a marked reduction in both to levels that are normal for healthy tendon. Critically, the collagen
matrix must resolve from small, randomly aligned fibres to large-diameter fibres with high packing density,
aligned with tensile loading forces. In addition, existing undamaged collagen bundles must be knitted back
into the new tissue. At the same time, a return to normal loading is essential in restoring normal structure
and, therefore, mechanical function.34,78 Why some tendons heal fully but many remain permanently in
a scar tissue or fibrotic stage is the necessary focus of much current research, as the dosing and timing of
potentially beneficial growth factor, stem cell and mechanical therapies require considerable optimisation.79
In this needle biopsy substudy, the effects of PRP were investigated 6 weeks after rupture and treatment
using relevant cellular markers.
Methods
Sixteen participants (nine in the PRP group and seven in the placebo group) were enrolled from a single
selected trial site and gave consent to undergo the sample collection procedure at 6 weeks post rupture.
Both the ultrasound radiologists and the tissue investigators were blinded to treatment allocation until
analysis was completed. A biopsy from the mid-lesion site was taken under guided ultrasound using a
14-gauge needle (Temno Evolution soft tissue biopsy needle; Merit Medical Systems, South Jordan, UT,
USA) slanted diagonally through the mid-line of the Achilles tendon, as previously developed by the trial
team.57 Tissue was collected into ice-cold phosphate-buffered saline and dissected immediately. Two-thirds
of the biopsy was fixed in 10% formalin, embedded in paraffin wax and sectioned longitudinally at 4-µm
thickness. One-third of the biopsy was snap frozen at –80 °C for follow-up studies.
Sections were stained by hand with routine haematoxylin and eosin or with picrosirius red (10 minutes
in 0.1% sirius red dissolved in 1% picric acid). Blood vessels were stained using a Dako Autostainer Link 48
for an angiogenesis marker [i.e. CD31 (Abcam clone C31.3; ab187377)] (Dako Agilent, Santa Clara, CA, USA).
A relevant mouse isotype control was undertaken and the detection system was horseradish peroxidase/DAB
(3,3′-diaminobenzidine) with haematoxylin counterstain (Envisage FLEX; Dako Agilent, Santa Clara, CA, USA).
Immunohistochemistry sections were imaged to include most of the biopsy area for CD31 (six viewing fields
at 200× magnification). Total cell count was obtained from haematoxylin-stained sections, using automatic
nuclear counts from six random fields at 400× magnification (ImageJ version 1.51s; http://imagej.nih.gov/ij;
accessed February 2019). Collagen density was assessed in four fields of view per section. In all fields of view,
large blood vessels and adipose tissue were avoided. Images were scored by a blinded assessor. A modified
Bonar scale81 was used and included analysis of the following components relevant to healing: (1) cellularity,
(2) collagen fibre density and (3) vascularity. Each variable was scored on a 4-point scale of 0–3 (0, normal;
1, slightly abnormal; 2, abnormal; and 3, markedly abnormal). The samples were scored according to whether
or not there was an abnormal appearance (i.e. hypercellular, hypervascular, low collagen). The total score
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varied between 0 (normal tendon) and 9 (severe abnormality).80,81 Treatment groups were compared using
two-tailed Mann–Whitney U-tests, with significance taken as a p-value of < 0.05.
Results
The bulk of tissue in all biopsies comprised abnormal tendon tissue in the process of active remodelling.
There were very few intact mature collagen bundles, while cellularity and vascularity were typically high
compared with normal tissue. One of the biopsies was severely compromised in cellularity and vascularity,
with minimal intact collagen. It is not possible to assess whether this was prevalent ahead of the rupture
injury or developed subsequently, but tissue repair could be challenging with few matrix-secreting cells
and absence of vascular remodelling, and this biopsy was scored as 3 (or abnormal) for all three Bonar
categories, as previously suggested.81 The participant in question did not have a re-rupture, suggesting that
the biopsy was not representative of the whole lesion.
In exploratory analysis, there were no detectable differences between placebo and PRP-treated groups in
either cellularity or vascularity (Table 20). However, the PRP group had lower collagen fibre density. Overall,
the combined Bonar score was higher for the PRP group.
Platelet-rich plasma quality was measured in substudy 1 for all participants randomised to receive PRP
injection. The nine participants from whom biopsies were obtained all received good-quality PRP with low
platelet activation on collection and containing high growth factor levels after activation.
Discussion
Biopsies were obtained from 16 participants from one centre who consented to this component of the
study. This substudy was intentionally exploratory so the sample size was accordingly limited and not
powered for detecting between-group differences in specific measurements.
Tendon healing at 6 weeks after an acute rupture should have significantly progressed but will not be
complete. Marked increases in both cellularity and vascularity must happen in order for healing to occur
but should then reduce to normal tendon levels. In humans, collagen synthesis and remodelling can be
expected to continue for months after the injury. Although Bonar and Movin scores have been developed
to assess tendinopathy rather than recovery from injury, they are frequently used for both.81,82 It is, in fact,
difficult to separate the two processes in a biopsy as many tendons will have ruptured because of prior
tendinopathy.8 In this study, the centre of the rupture lesion was biopsied and the main difference in
interpretation of scores is that an injured tendon in the process of healing has high cellularity, reduced
and more-diffuse collagen and elevated vascularity, which are also common signs of tendinopathy in an
uninjured tendinopathic biopsy. A badly compromised injured tendon will have very few cells (low score),
massive collagen loss (high score) and few blood vessels (low score), which, overall, could score quite low
or ‘good’ on a tendinopathy scale, but is clearly abnormal. It is therefore useful to consider relative
differences between groups rather than absolute score.
Although all biopsies except one showed evidence of healing at 6 weeks, there was less collagen fibre density
in the PRP group. This did not correlate with differences in cellularity or vascularity, as these parameters were
similar in both groups, suggesting equivalent healing processes. There are several possible explanations. The
collagen may be forming more slowly in the PRP-treated group or may have been subjected to an early phase
of breakdown and is still catching up at 6 weeks. This was a small study of 16 biopsies, which might be prone
to chance allocation. Ultimately, the speed of return to full function and the long-term re-rupture rate will
indicate whether this difference in healing process is beneficial, negative or unimportant.
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TABLE 20 Statistical analysis of the groups according to Bonar scoring
Bonar score
Intervention group, Bonar score
p-value
Placebo PRP









Cellularitya 1.71 (0.49) 2 (1–2) 5 0.71 1.89 (0.60) 2 (1.5–2) 6 0.67 0.665
Collagen stainb 1.14 (0.38) 1 (1–1) 6 0.86 2.00 (0.50) 2 (2–2) 7 0.78 0.007
Vascularityc 0.42 (0.53) 0 (0–1) 4 0.57 1.11 (1.05) 1 (0–2) 3 0.33 0.201
Bonar score totald 3.28 (0.76) 3 (3–4) 3 0.43 5.00 (1.87) 5 (3.5–6) 2 0.22 0.038
IQR, interquartile range.
a Cellularity score: 0 = low normal, 1 = moderate, 2 = high, 3 = abnormal.
b Collagen-density score: 0 = dense, 1 = good, 2 = dispersed, 3 = low/abnormal.
c Vascularity score: 0 = low normal, 1 = moderate, 2 = high, 3 = abnormal.













































































































































































In this chapter, we summarise the main findings of the clinical trial and both substudies before consideringthe internal and external validity of the trial. Interpretation of the results and their relationship with other
literature are discussed, followed by consideration of the implications for clinical practice and future research.
Aim and overview of clinical trial findings
Our primary objective was to evaluate the clinical efficacy of PRP among patients with acute ATR using an
objective measure of muscle–tendon function, the LSI of work performed during the HRET at 24 weeks
post randomisation. PROMs were used to study function, symptoms, pain and quality of life. An analysis
of whole-blood and PRP biological components was embedded in the trial in order to determine key
components of PRP that may contribute to its mechanism of action and to enhance quality assurance
during the trial. A second substudy to explore the possible tissue and immunohistochemical effects of
PRP on the healing tendon tissue compared with those of the control was also embedded in the trial
and included 16 participants. Investigating efficacy and mechanism together in the present trial provides
robust information on PRP application in ATR and offers a rigorous platform for future research into PRP
applications in musculoskeletal problems.
This was a prospective, multicentre, parallel-group, participant- and outcome assessor-blinded, randomised,
placebo-controlled superiority trial. A total of 230 patients presenting with acute ATR within 12 days of
injury were recruited in 19 NHS hospitals in England and Wales.
We found that PRP was not effective in improving muscle–tendon function 24 weeks after acute ATR.
There were also no differences in the secondary outcome measures of patient-reported function, symptoms,
quality of life and pain at 24 weeks. There were no statistical differences in all secondary outcome measures
between the PRP group and the placebo group throughout the follow-up period, indicating that there was
no early acceleration of recovery. Including stratification factors and other predefined prognostic variables in
the analysis, when relevant, had no impact on the attained primary and secondary outcome results. CACE
and sensitivity analyses demonstrated that the conclusions were robust under a range of assumptions.
The PRP group and the control group had nearly the same rate of re-rupture, surgical repairs, swelling, DVT,
skin breakdown or ulceration, swelling and casting-related complications. Secondary surgical intervention to
repair the Achilles tendon was required by 4% (9/229) of participants; this was carried out on participants
who failed non-surgical treatment and had re-rupture of the tendon.
Blood and platelet-rich plasma substudy findings
An analysis of whole-blood cellular composition showed that the two groups had similar baseline blood
parameters. PRP analysis showed that the preparation method resulted in a mean 4.1-fold increase in
platelet count and a 2.2-fold increase in white blood cell count compared with whole blood. The majority
of platelets in the PRP were of good quality with low levels of activation. The PRP produced using the trial
procedures was therefore functional, with the majority of platelets in the PRP preparations being shown
to be capable of activation and degranulation, with a few exceptions. As would be expected, there was
correlation between platelet and leucocyte counts and some growth factor concentrations.
Despite using a standardised preparation method to manage operator error, there was wide variation in
platelet count, white blood cell count and growth factor concentrations; this indicates the variable nature
of this biological product. However, this did not have an effect on the clinical outcome.
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Clinical outcomes and platelet-rich plasma analysis correlation
Parameters of baseline whole blood taken before intervention in both groups did not correlate with the
primary outcome measure at 24 weeks.
Overall, there was no association between PRP cellular or growth factor content on the primary outcome
measure. The level of platelet activation and white blood cell concentration at baseline also did not correlate
with the primary outcome. The results of this mechanistic analysis confirmed that any variability in this
biological product did not change the outcome of ATR management.
Immunohistochemistry study findings
In substudy 2, with 16 participants, all except one biopsy showed evidence of healing at 6 weeks. There
was less collagen fibre density in the PRP group. This did not correlate with differences in cellularity or
vascularity, as these parameters were similar in both groups, suggesting equivalent healing processes.
The findings of this substudy could indicate that collagen was forming more slowly in the PRP group or
was subjected to early breakdown at this early 6-week stage. However, this was a small-scale study,
meaning that cautious interpretation is required.
The findings of this study could not be linked to the clinical outcome because of the small number of
biopsies undertaken.
Internal validity and methodology
The trial was powered to be a definitive superiority trial and had lower than expected loss to follow-up.
Blinding of participants and outcome assessors and low levels of missing data across the outcome measures
strengthen the trial results. Allocation concealment was ensured through random computer allocation,
stratified by site and age, on participant registration via a remote computer randomisation service. Analyses
were pre-planned and agreed by the DSMC.
Platelet-rich plasma quality control and measurements in substudy 1 enabled ongoing monitoring during
the trial so that any issues could be resolved. Measuring PRP activation and viability allowed us to ensure
that viable PRP was injected and also allowed the correlation with the clinical primary outcome measure.
During the initial phase of the trial, four PRP samples showed very low platelet counts. The trial was
temporarily halted and preparation methods, devices and kit were tested. This was thought to be due to
faulty sensors in some devices. Those devices and kits were replaced and the trial continued without any
further issues of that nature.
Platelet-rich plasma products vary according to preparation techniques and devices.83 In this trial,
standardising the preparation method and providing the same kit and PRP preparation devices to all
centres ensured that any significant variability due to different preparation techniques and devices was
eliminated. The results of substudy 1 still show variability in PRP content and activation; however, this is
probably due to the variable nature of this biological product rather than preparation methods.
Complier-average causal effect analysis was used to estimate the treatment effect while accounting for
whether participants complied or did not comply with the treatment allocated to them (without assuming
that compliers were the same as non-compliers as would be the case with PP analysis). The consistency
between the conclusions of the mITT findings and CACE analysis improves the confidence in the findings
of the PATH-2 trial.
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The validation checks on the HRET (see Appendix 3) identified invalid data on a small number of
participants and it was reassuring that the conclusions from the estimates with raw HRET data and those
with valid data after the checks were consistent. To dismiss potential measurement errors, two members
of the trial team who were blinded to treatment allocation reviewed the videos of all assessments
independently and any invalid heel-raise repetitions included in the HRET data were discounted. The test
was standardised through training the blinded assessors and by offering trial-specific guidance notes and
videos.
In the context of the PATH-2 trial, the conclusions drawn from the work LSI are supported by the high
precision of estimates and the consistency with the secondary outcomes (ATRS, PSFS, SF-12 and VAS).
On formal analysis, the success of the outcome assessor blinding at the end point was adequate. Both
the James et al.69 and Bang et al.70 blinding indices gave evidence to support the assumption that, overall,
participants in this trial were blinded. This demonstrates that the findings of this trial are extremely unlikely
to be due to participants’ expectations of treatment received.
External validity and generalisability
The trial was conducted in acute hospitals, from major trauma centres through to smaller district general
hospitals, and, therefore, is representative of the range of settings for ATR management in the UK. The
PRP and placebo interventions were delivered by NHS trauma and orthopaedic teams with relatively little
trial-specific training. Rehabilitation guidelines were set to augment some standardisation of care for
trial participants. All participants should therefore have had their injured lower limb immobilised for at
least 3 weeks after injection, avoided more than 6 weeks of rigid full-time immobilisation without ankle
motion or weight-bearing and received a referral for physiotherapy. Compliance with these different
aspects was measured and was good, with no difference between treatment groups.
The demographics of the trial participants were representative of the age and sex profile expected of adults
with ATR,9 with the majority being male and aged < 55 years. Excluding patients with rupture of the Achilles
tendon at the insertion or musculotendinous junction limits generalisability. However, the healing in these
areas is usually better than that of mid-substance rupture.8
The primary end point at 24 weeks could be considered too early for definitive assessment of outcome.
However, a difference in speed of healing should have been seen when the tendon is in the recovery phase,
and our PATH-2 trial primary outcome measure at 24 weeks post injury is timed to capture this. In addition,
the theoretical mode of action of PRP by enhancement of cellular response in the early inflammatory healing
phase would be expected to peak in the early stages of Achilles tendon repair. A meta-analysis32 demonstrated
that improvement of patient outcomes from previously published studies of ATR showed that most
improvement occurs in the first 6 months, which, therefore, supports this as the definitive assessment point.
There were no discernible differences between groups in relation to the grade of the clinician administering
treatment. Notably, the clinicians were mostly consultant surgeons (75%) and surgical registrars (17%).
A number of extended-scope physiotherapists and research fellows have applied the intervention, reflecting
the range of clinicians in contemporary orthopaedic clinical practice.
Implications for clinical practice
Achilles tendon rupture leads to a major impairment in function, irrespective of the treatment received.
The findings demonstrate that participants recovered < 40% of the muscle–tendon unit function
at 24 weeks. This observation is also supported by the secondary outcome measures ATRS and PSFS.
The majority of participants continued to experience pain at the end point, although of significantly less
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severity than at baseline. This underlines the impact of this injury on individuals in terms of day-to-day
activities, as well as the wider socioeconomic impact.
The PATH-2 trial results are important for clinicians practising in this field who are aware of PRP use and
who may receive requests from patients to administer PRP by injection. These results challenge the growing
use of PRP in ATR. For patients, who are increasingly being involved in decision-making about their
treatments, these findings are an important contribution to that discussion. The similarity in the primary
outcome findings at 24 weeks and for the patient-reported secondary outcomes throughout follow-up
strongly support the validity of the conclusion that PRP does not improve the outcome of ATR management.
Therefore, the application of PRP for this indication appears unjustified and without benefit.
The trial results also showed that injection is associated with some AEs at the injection site, with 11 out of
229 (5%) participants reporting frequent discomfort and 3 out of 229 (1%) participants reporting clinically
diagnosed infections. However, no clinically serious infections were reported.
Re-rupture rates were low in both groups, but it should be noted that the trial was not powered to detect
a between-group difference for this outcome.
Platelet-rich plasma application in clinical settings has a significant cost implication for health-care providers.
Although we did not carry out a health economic analysis, applying PRP in ATR management will add to
the cost of standard care. The cost of applying PRP is variable, but includes (1) a centrifuge, (2) a PRP
disposable kit per patient, (3) an injection kit, (4) blood withdrawal and preparation time (15–30 minutes)
and (5) surgeon or practitioner injection time (10 minutes).
In addition, PRP injection is usually administered in a fracture or trauma clinic in NHS hospitals, which are
busy, with limited time and space allocation for each patient. The time taken to withdraw blood and
prepare the PRP and the injection may have an impact on patient flow in those clinics. The injection is
usually administered in a clinic room or cubicle and adds to the burden on clinic staff.
A recent report estimated that the value of the PRP market was US$214.3M in 2016, which is expected to
reach US$625M globally by 2025.84 This market estimate does not include the cost to health-care providers
in terms of staff and clinic space; however, it does include PRP applications in all specialties. PRP application
in sport injuries in Europe is rapidly increasing.85 Current PRP cost in ATR is unknown but likely to be
growing.85 The findings of this trial will help inform clinical decision-makers, commissioners and payers for
health-care services and may limit the cost burden of PRP in ATR management.
Limitations
In the PATH-2 trial, we used and assessed a single PRP preparation system based on a previous study86 to
standardise the procedure. There are three methods to prepare PRP: (1) gravitational platelet sequestration
or centrifugation, (2) standard cell separators and (3) selective filtration technology or plateletpheresis.
Clinically approved devices use one of these methods to produce PRP from autologous blood with varying
concentrations and platelet yields. We selected a fully automated system that utilises infrared sensors to
detect platelet layers in the centrifuged blood and automatically load it to a syringe, ready to be injected.
Our tests of this device and the PRP method in the pilot study importantly demonstrated a viable product
and a reliable preparation system. All PRP preparation devices produce varying concentrations of platelets
and white blood cells; however, we have shown in this trial that there was no link between platelet count
or white blood cell count and the clinical effect.
Nine per cent of participants in the PRP group did not receive the allocated treatment. The allocated
intervention for participants in the PRP group was dependent on the ability to withdraw sufficient whole
blood to produce the required 8-ml PRP sample, a fully working centrifuge, an available in-date PRP
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preparation kit and patients willing to wait the time for the preparation. This reflects the reality of this
intervention in usual acute NHS hospital settings.
Standardising the rehabilitation protocol across sites can hinder the pragmatic approach of the trial.
Within an agreed common approach, we allowed rehabilitation to be tailored to the participant and local
provision. All participants had to be referred for physiotherapy but then it was the responsibility of the
therapy service to provide what was their usual care. This pragmatic approach may have resulted in some
site-to-site variation in provision, but we stratified randomisation and adjusted primary treatment estimates
on centre to help manage this.
Documentation of medication that may have an effect on platelet function, such as aspirin or clopidogrel,
was not requested until after the trial had started; therefore, information on this was available for only
65% of patients. Only 5.7% of patients who were asked about this were on antiplatelet medication,
and this was similar between the two treatment arms; therefore, it was unlikely to have an influence on
outcomes.
The timing of the primary end point (24 weeks) may be considered early for final functional recovery of
the tendon. However, the results indicate no effect at this early stage when PRP was expected to exert its
maximum effect in enhancing recovery. A 2-year follow-up of patient-reported data is being conducted
and the results will be reported in due course.
The number of histological study biopsies was too small to secure statistically significant results of the
effect of PRP on the tendon tissues. The substudy findings were intentionally considered exploratory and
indicative rather than confirmative of the changes in the healing tendon. The limited number of biopsies is
within the generally accepted range for similar studies on human participants.
Further research
The PATH-2 trial found no evidence of efficacy for PRP in the treatment of acute ATR. The implications
are that similarly robust clinical trials are recommended for investigating the efficacy of PRP applications for
other musculoskeletal disorders.
The extent of muscle–tendon impairment identified in the HRET in the injured limb, irrespective of
treatment group, highlights the degree of ongoing musculotendinous unit compromise 6 months after
tendon rupture. Although musculotendinous impairment has been found in other ATR cohorts,35 the
extent of asymmetry between injured and uninjured legs in this trial was substantial. Optimising recovery
of neuromuscular function during rehabilitation is therefore a recommended area of future investigation.
There were some variations in the non-surgical management of acute ATRs within the range permitted in
the standardised rehabilitation guidelines for the PATH-2 trial. An ongoing clinical trial funded by the NIHR
Health Technology Assessment programme (project number 13/115/62) will provide additional evidence
regarding the clinical effectiveness and cost-effectiveness of two commonly used protocols: plaster casting
versus a rigid functional brace with immediate weight-bearing.87
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Appendix 1 The PATH-2 trial: trial management
Introduction
The PATH-2 trial completed recruitment on schedule against the plans agreed with the funder (Figure 21)
and also obtained very good levels of follow-up and a relatively low number of missing outcome data.
We believe that an experienced, dedicated, trial management team that could apply the same depth
for both the scientific elements and the clinical elements of the study in addition to the dedication of the




















































































FIGURE 21 The PATH-2 trial recruitment against the original and revised targets.
TABLE 21 The PATH-2 trial management milestones
Planned activity to be completed
Project month in project
management plan
agreed with funder,





September 2017 Actual month or date
First TMG meeting, finalise protocol 1 (October 2014) 21 March 2014
Obtain ethics approval 3 (December 2014) 11 November 2014
First DSMC meeting 6 (March 2015) First DSMC/TSC meeting,
31 July 2015
Second DSMC meeting 16 (January 2016) First DSMC meeting,
22 January 2016
Second TSC meeting 17 (February 2016) First TSC meeting,
4 March 2016
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Recruitment target and site selection
The original application predicted a recruitment rate of one patient per participating centre per month,
which required a total of 15 sites to be opened at the rate of one per month.
Some sites expressed interest in the trial after seeing a notice on the NIHR website or information
disseminated through the clinical research networks. Sites that had participated in our previous AIM
(Ankle Injury Management) trial88 and sites with a surgeon who was a member of the British Orthopaedic
Foot and Ankle Society were approached if it was thought that their catchment area was large enough.
TABLE 21 The PATH-2 trial management milestones (continued )
Planned activity to be completed
Project month in project
management plan
agreed with funder,





September 2017 Actual month or date
15 sites open to recruitment
(sites recruitment ends)






26 (November 2016) Superseded; recruitment
target changed
Substudy 2: 16 biopsies taken place
(recruitment to substudy 2 closes)
26 (November 2016) October 2016 11 August 2016
Substudy 1: 107/214 PRP/blood
samples collected for analysis
27 (December 2016) Superseded; recruitment
target changed
Substudy 1: platelet analysis finalised 27 (December 2017) November 2017 March 2018
Third DSMC meeting 28 (January 2017) January 2017 Third DSMC meeting,
3 February 2017
Third TSC meeting 29 (February 2017) October 2016 Second TSC meeting,
14 October 2016
214 24-week follow-ups completed
(primary outcome data collection ends)
32 (May 2017) Superseded; recruitment
target changed
Substudy 2: biopsy analysis finalised 32 (May 2017) May 2017 April 2018
Final data cleaning 32 (May 2017) March 2018 June 2018
Fourth TSC meeting July 2017 Third TSC meeting,
21 July 2017
Substudy 1: growth factor analysis
finalised
34 (July 2017) August 2017 March 2018
230 patients recruited
(recruitment closes)
September 2017 18 September 2017
Substudy 1: 115/230 PRP/blood
samples collected for analysis
September 2017 September 2017
Second DSMC/TSC
meeting, 29 June 2018
Site close-out completed June 2018 Ongoing
Data analysis 34 (July 2017) July 2018 July 2018
Write-up of draft final report and
publications
35 (August 2017) April 2018 14 August 2018
Dissemination of findings 35 (August 2017) July 2018 August 2019
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Sites then completed a site feasibility questionnaire, which included their predicted recruitment rate. We
continued negotiation with sites that predicted at least one participant per month after allowing for patients
opting for surgery and patients who declined to participate. Site initiation visits were held, mostly in person,
although some via teleconference, at which the remaining procedures were discussed and any potential
problems were raised.
Establishing collaborating sites was hampered due to their inability to obtain excess treatment costs (ETCs),
which were required to purchase trial-specific centrifuges for trial treatment. Sites could not obtain local
NHS trust research and development approval until funds for the equipment were in place. The chief
investigator purchased a small number of centrifuges, allowing two sites to open to recruitment, while
addressing the ETC issue, and in December 2015 the Department of Health and Social Care agreed that
the PATH-2 trial could apply for a subvention to purchase the equipment. There was further delay while
the centrifuges were shipped from the US manufacturer. The start of patient recruitment was delayed from
April 2015 to mid-July 2015. The funder was informed of every development throughout.
In February 2016, the recruitment forecast was re-profiled based on the delay to the start of recruitment
and the rate of recruitment at that time (0.75 participants per site per month) and the go/no-go (G/NG)
decision point 2 was pushed back from 1 May 2016 to 1 July 2016. One site closed early by mutual
agreement with the PI as they had not recruited any participants and all patients were choosing surgery,
which made them ineligible for the PATH-2 trial. It was agreed that four more sites would be opened to
guard against lower than expected recruitment in some newly opened sites. Finally, 18 sites were opened
to recruitment.
In July 2016, after the stop/go decision point, a 9-month extension was agreed with the funder, moving
the expected end of recruitment to July 2017.
In June 2017, with approximately half of the sample having reached their 24-week follow-up point,
variability was looked at for 75 participants with valid cleaned data (SD 24), and found to be greater
than that assumed for the sample size calculation (SD 20). To maintain the integrity of the trial data,
we proposed continuing recruitment to 229 participants, which would give 80% power to detect a 10%
difference (standardised effect size of 0.5) with 20% loss to follow-up (although this was running at 15%).
This meant extending recruitment into September 2017, instead of finishing at the end of July 2017
as planned. The DSMC assisted with the proposal and recommended this course of action, and it was
supported by the TSC. The funder approved a 2-month no-cost extension and the recruitment target was
raised to 230, which was reached in September 2017.
Go/no-go assessment
Go/no-go decision points formed part of the contract with the Department of Health and Social Care
for the deliverability of the PATH-2 trial. The purpose of G/NG decision points is for the Efficacy and
Mechanism Evaluation programme to review whether or not funding should continue at each identified
stage of the project. Two G/NG decision points were specified as follows:
1. Go/no-go decision point 1 (G/NG 1). The milestone for G/NG 1 was ethics approval being sought and
approved within 2 months of the project start date. As the project start date was 1 October 2014 and
favourable ethics opinion was granted on 11 November 2014, this milestone was achieved.
2. Go/no-go decision point 2 (G/NG 2). The milestones for G/NG 2 were to be assessed in May 2016,
10 months into the recruitment stage, when approximately 50 participants were to have been recruited.
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The DSMC was requested to report on the following milestones for G/NG 2:
l safety of the intervention
l site recruitment (consider stopping if seven out of a planned 15 sites were not recruited)
l participant recruitment (consider stopping if < 20% of eligible patients who were approached
had consented)
l intervention compliance (consider stopping if < 80% of participants who started their allocated
treatment were compliant)
l follow-up compliance (consider stopping if loss to follow-up at week 24 was > 30%).
Data on safety, trial conduct and feasibility were reported to the DSMC, which made recommendations
about the continuation or otherwise of the trial to the TSC, which made the final decision about the
continuation or otherwise of the trial.
In October 2016, the funder approved an amendment to extend recruitment by 9 months and the G/NG
position was moved to 1 July 2016. The reasons for the extension were as follows:
l Delay in site recruitment – establishing collaborating sites was hampered due to sites’ inability to
obtain ETCs, which were required to purchase upfront trial-specific centrifuges for trial treatment.
In January 2016, we received formal notice that a subvention would be provided by the Department of
Health and Social Care to cover the ETCs (to purchase the centrifuges). We proceeded to order centrifuges
for trial sites from the supplier.
l Sites halting recruitment for 1 month because of a quality issue with PRP samples that were produced
in the trial-specific centrifuges. The issue was investigated with the help of the supplier and did
not recur.
Following a database lock on 4 July 2016, the DSMC chairperson wrote to the funder to confirm that the
milestones had been met as follows:
l Number of sites open to recruitment (seven expected) – 12.
l Proportion of patients consented/eligible (at least 20%) – 65% (75/116).
l Number of participants randomised (50 minimum) – 75.
l Compliance with intervention (80% minimum) – 96%.
l Losses to follow-up (< 30%) – 0%.
l Safety – no SAEs were reported by the randomised participants up to the stop/go point. Six AEs
were reported.
The DSMC confirmed that the trial met the G/NG milestones and that the trial should continue.
Monitoring of trial recruitment
Sites completed a monthly screening log, declaring all patients who had presented to the emergency
department or specialist fracture clinic or foot and ankle clinic with a suspected ATR. Reasons for not
recruiting were monitored centrally and trends were identified. In response, certain eligibility criteria
were revisited early in the trial: sites with a single weekly fracture clinic could not always randomise
participants within the required 7 days from injury, so the criterion was changed to within 12 days from
injury; some otherwise-healthy patients were excluded because they were aged > 70 years, so the age
criterion was removed and a criterion of ‘ambulatory prior to injury’ was implemented. These two changes
to eligibility criteria were implemented in a change to the protocol in March 2016.
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We were alert to repeated reports at certain sites, such as patients being missed because they were treated
at the weekend when there were no research staff present, or higher than expected rates of patients
choosing surgery. This led to discussions with the sites to explore possible solutions, and identification of
one site where all patients were having surgery and no patients were recruited. Once this was recognised,
it was decided to close the site, by agreement with the PI. A minority of patients declined participation
because they were uncomfortable with injections or blood being taken, and it was discussed with sites
how this could be introduced to the patients in a less concerning fashion.
Data management
According to the standard operating procedures of the OCTRU, data management procedures were
defined in a data management plan. This covered trial databases and data handling, definition of critical
data fields, forms and questionnaires used, how protocol deviations were recorded, data rulings, handling
data deviations, data security and confidentiality, data set closure, archiving and data sharing. Each data
management plan version was signed off by the chief investigator and trial statistician.
The monitoring plan determined the need for central and on-site data monitoring. All sites were monitored
centrally, and 12 sites underwent a site monitoring visit, either routine (n = 8) or triggered by a concern
(n = 4).
Statistics on data collection, data entry and query management were presented to each TMG meeting for
oversight.
Trial promotion
Promotion to patients and the public
Each recruiting centre displayed an ethics-approved patient poster in the fracture clinic, to make patients
aware of the trial before they were approached to participate.
The PATH-2 trial has a public-facing web page on the OCTRU trials website (https://path2.octru.ox.ac.uk/;
accessed August 2019), where trial information, current recruitment figures and news are publicised. An
additional page called Reach Target Event was created in April 2018 with the aim of encouraging site staff to
screen and recruit all eligible patients. This was promoted as an alternative to a study day for site staff, and
included videos about the trial and the scientific objectives, discussion forums, competitions and cartoons.
The Reach Target Event page is now available to the public and was entered into NIHR’s ‘Let’s Get Digital’
competition in June 2017.
Promotion within the trauma and scientific communities
The PATH-2 trial design has been presented at:
l the fifth NIHR Musculoskeletal Trauma Trials Annual Meeting, Warwick, 11 January 2017
l the Trauma Orthopaedic Research Collaboration, Oxford, 6 October 2017
l the sixth NIHR Musculoskeletal Trauma Trials Annual Meeting, Bristol, 10 January 2018
l the fourth Annual Celebrating Trauma Research in the Thames Valley, Reading, 28 February 2018
l Tendon UK, Oxford, 11–12 April 2018.
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Appendix 2 Development of heel-rise endurance
test outcome measures
Background
The HRET was introduced over 30 years ago as an objective outcome measure for assessing functional status
following ATR.68 The HRET involves repetitive concentric–eccentric muscle actions of the plantar flexors
in a single-leg stance until exhaustion, with performance quantified by the number of raises (repetitions)
performed.89 Subsequently, the HRET has been consistently employed as an outcome measure in studies
of ATR rehabilitation.86,90–95 However, reporting of test standardisation procedures has been poor and, to our
knowledge, no universally acceptable test parameters have been published to date.89 A systematic review of
the test identified six key testing parameters required for adequate standardisation of the test that have been
reported inconsistently: (1) ankle starting position, (2) knee starting position, (3) height of heel raise, (4) pace
(raises per minute), (5) balance support and (6) test termination criteria.89 In addition, the use of repetitions
as the primary outcome measure in the majority of studies represents a crude and insensitive measure
of function as this outcome provides little information on the quality (height) of movements performed.
This is important as tendon elongation and disproportionate strength loss at the end of plantar flexor range
are two impairments in ATR that are not adequately assessed by a simple measure of repetitions. Therefore,
standardisation of testing parameters and selection of outcome measures that are sensitive to ATR functional
impairments were the two key areas identified for test development.
Nilsson-Helander et al.65 advanced HRET methodology by introducing a measuring device in the form of a
linear displacement sensor attached to the participant’s heel, which enables the height of each repetition
to be measured and three outcome measures quantified: (1) number of repetitions, (2) total work in J
and (3) maximum heel-rise height in cm. Their results revealed that work as an endurance measure and
maximum height as a measure of tendon function are more sensitive impairment outcome measures than
repetitions following ATR. For example, repetitions classified the percentage of patients having normal
function (defined as injured limb performance of ≥ 90% of the uninjured limb) at 6 and 12 months after
ATR as 38% and 63%, respectively. This compared with 9% and 23% for work and 6% and 22% for
maximum height at 6 and 12 months, respectively. Work and maximum height (but not repetitions) also
demonstrated significant positive associations at 6 months post ATR with the Achilles tendon Total Rupture
Score, a validated PROM being employed in the PATH-2 trial. Deficits at the 6- and 12-month follow-ups
were 39% and 24% for endurance (work), 28% and 20% for maximum height and 26% and 5% for
repetitions, respectively.65 In addition, the deficit in maximum height was significantly and highly correlated
with Achilles tendon elongation at 6 months (r = –0.94; p = 0.002) and 12 months (r = –0.74; p = 0.037).96
Further studies have demonstrated that work and maximum height are sensitive to, and predictive of,
long-term residual impairments.97 Both remain significantly impaired at 2 years post ATR, with the majority
of recovery occurring in the first 6 to 12 months,97 and deficits at 12 months correlate with abnormal ankle
movement and force during walking, jogging and jumping activities at 6 years post ATR.98 On the basis of
current evidence, the use of a linear encoder measurement device during the HRET to provide outcome
measures of work and maximum height represents the best available method of assessing ATR rehabilitation
in a clinical setting and was adopted for the PATH-2 trial.
Heel-rise endurance test methodology development
The aims of the HRET development work were to (1) develop standardisation procedures for the HRET,
(2) develop clinician training material and participant information, (3) develop easy-to-use HRET software
and secure data-transfer procedures for clinician outcome assessors and (4) determine the test–retest
reliability of HRET outcome measures when applying our procedures.
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Standardisation procedures
A linear encoder, consisting of a spring-loaded cord connected to a linear displacement sensor with a
measurement resolution of 0.019 mm and a sample rate of 200 Hz, and data-collection software were
loaned for pilot testing from a commercial supplier (Encoder and MUSCLELAB™ software, Ergotest
Innovation A.S., Porsgrunn, Norway). The key testing parameters identified by Hébert-Losier et al.89
were used to aid standardisation of the HRET. In addition, we developed a standardised warm-up for
participants that was suitable for a clinical environment, consisting of 5 minutes of usual-pace walking
followed by 10 double-leg heel raises. The following standardisation parameters were adopted: (1) ankle
starting position of 10° dorsiflexion produced by conducting the HRET on a custom-made 10° incline box,
(2) knee starting position of full extension, (3) height of each repetition to be as high as possible, (4) pace
of 30 raises per minute guided by a digital metronome, (5) balance support by the fingertips only and
(6) strictly defined test termination criteria. The criteria for the end of the HRET were that participants
either stopped (i.e. volitional task failure) or were audibly instructed to stop with both feet flat on the
box whenever any of the following test termination criteria were observed: (1) inability to keep pace with
the metronome, (2) inability to maintain full knee extension of the standing leg or (3) using more than
fingertip support. The desired end point was volitional task failure; however, outcome assessors were
encouraged to use verbal prompts whenever the termination criteria were observed and to stop the test if
the participant did not respond to two consecutive prompts. In accordance with Nilsson-Helander et al.,65
three outcome measures were established: (1) total work in J, (2) number of repetitions and (3) maximum
heel-rise height in cm. Each could be expressed as a LSI, with the injured limb performance as a percentag
of the uninjured limb performance. Total work LSI was selected as the primary outcome measure as this
indexe provides a measure of plantar flexor muscle endurance and Achilles tendon function as it incorporates
the maximum height of each repetition. Total work (J) was computed as the product of body mass (kg),
total vertical displacement (m) and the constant 9.807, converting kilopond metres to J.
Software and training materials
The MUSCLELAB™ software was deemed too complex for use in a clinical environment and a simpler
clinician-facing software was designed by the PATH-2 trial team incorporating our own standardised
procedures and produced by a commercial partner (PATH-2, MUSCLELAB™, Ergotest Innovation A.S.).
Key features of this software were step-by-step instructions for the conduct of the test and the addition and
integration of a video-recording of each test, which enabled a post-HRET evaluation of the integrity of each
test by the PATH-2 trial team. Standardised participant information and instructions for the HRET involved
the participant watching a video demonstration of the HRET and reading standardised written instructions
detailing their expected conduct during the test and the test termination criteria. At test completion, the
software also guides the clinician on secure participant HRET data transfer by encrypted USB. The HRET
equipment and software were packaged with clinician training material, consisting of high-quality training
videos created by the PATH-2 trial team and produced by Oxford Medical Illustration, and a training and
reference manual. Face-to-face training would be delivered by a member of the PATH-2 trial team to each
clinician outcome assessor prior to their first participant’s 24-week follow-up appointment.
Heel-rise endurance test reliability study
Following the establishment of our standardisation procedures, a reliability study was conducted on 38
healthy participants [18 males and 20 females; mean age 36 years (SD 9 years)], mean body mass 71.5 kg
(SD 15.3 kg). The findings were reported in accordance with guidelines for reporting reliability and agreement
studies,99 and were published in 2017.100 Reliability was assessed by the intraclass correlation coefficient (ICC)
and agreement was assessed by a range of measures including the standard error of measurement (SEM),
coefficient of variation (CV) and 95% limits of agreement (LoA). Reliability for repetitions (ICC 0.77, 95% CI
0.66 to 0.85) was equivalent to work (ICC 0.84, 95% CI 0.76 to 0.89) and maximum height (ICC 0.85,
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95% CI 0.77 to 0.90). Agreement for repetitions (SEM 6.7, 95% CI 5.8 to 7.9; CV 13.9%, 95% CI 11.9%
to 16.8%; 95% LoA –1.9% ± 37.2%) was equivalent to work (SEM 419 J, 95% CI 361 J to 499 J; CV
13.1%, 95% CI 11.2% to 15.8%; 95% LoA 0.1% ± 34.8%), with maximum height being superior
(SEM 0.8 cm, 95% CI 0.6 cm to 1.0 cm; CV 6.6%, 95% CI 5.7% to 7.9%; 95% LoA 1.3% ± 17.1%).
We found that work and maximum height demonstrated acceptable reliability and agreement that were at
least equivalent to those of the traditional repetitions measure.
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Appendix 3 Additional results
Participant reporting of pain
One potential issue of injecting PRP into an ATR site is that, by introducing fluid into this area, increased
pain may be experienced immediately after. However, there is a possibility that, over time, any pain
experienced by participants may reduce faster if PRP has been received, due to the assistance in healing
that is offered. As a result, any severe pain experienced by participants was explored, alongside the
information relating to pain as reported in their pain diaries, completed daily for the first 2 weeks. The
results from these explorations are given in Table 22 and offer no evidence to suggest any difference
between intervention groups in pain experienced.
Participant employment and academic characteristics
The academic and employment characteristics of participants, as recorded at baseline, are presented
in Table 23.
Participants’ pre-injury clinical characteristics
The health of an individual not only affects their risk of experiencing an injury but can also affect their
healing. At recruitment, participants were excluded if they were identified to have any medical conditions
that would make them unsuitable for this trial. However, at baseline, information on additional medical
conditions and medications taken by participants was collected. The summary of this information by
intervention group is given in Table 24.
TABLE 22 Pain reported by participants 24 weeks after injury, by intervention group
Pain measure
Intervention group, n (%)
Total (N= 229), n (%)PRP (N= 113) Placebo (N= 116)
Severe pain at the injection site requiring more than simple pain relief
No 102 (90.27) 106 (91.38) 208 (90.83)
Yes 4 (3.54) 2 (1.72) 6 (2.62)
Missing 7 (6.19) 8 (6.90) 15 (6.55)
Pain reduction in first 2 weeksa
No 18 (15.93) 21 (18.10) 39 (17.03)
Yes 74 (65.49) 63 (54.31) 137 (59.83)
Missing 21 (18.58) 32 (27.59) 53 (23.14)
a Calculated as VAS pain score on day 14 compared with VAS pain score on day 1.
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TABLE 23 Academic and employment-related characteristics of participants, by intervention group
Academic/employment status
Intervention group, n (%)
Total (N= 229), n (%)PRP (N= 113) Placebo (N= 116)
Academic status
Full-time student 0 (0) 4 (3.45) 4 (1.75)
Part-time student 2 (1.77) 0 (0) 2 (0.87)
Not studying 111 (98.23) 112 (96.55) 223 (91.38)
Employment statusa
> 40 hours/week 40 (36.04) 39 (34.82) 79 (35.43)
25–40 hours/week 46 (41.44) 49 (43.75) 95 (42.60)
10–25 hours/week 5 (4.50) 9 (8.04) 14 (6.28)
< 10 hours/week 2 (1.80) 2 (1.79) 4 (1.79)
Unemployed, looking for work 3 (2.70) 1 (0.89) 4 (1.79)
At home/not looking for paid employment 2 (1.80) 4 (3.57) 6 (2.69)
Unable to work owing to illness or disability 1 (0.90) 0 (0) 1 (0.45)
Fully retired (no paid work) 12 (10.81) 8 (7.14) 20 (8.97)
Type of workb
Office based 42 (45.16) 47 (47.47) 89 (46.35)
Shop work or similar 5 (5.38) 4 (4.04) 9 (4.69)
Classroom or equivalent 11 (11.83) 11 (11.11) 22 (11.46)
Physical outside work 6 (6.45) 10 (10.10) 16 (8.33)
Physical indoor work 8 (8.60) 15 (15.15) 23 (11.98)
Mainly travel/on the road 6 (6.45) 3 (3.03) 9 (4.69)
Other 15 (16.13) 9 (9.09) 24 (12.50)
Childcare 0 (0) 1 (1.01) 1 (0.52)
Driving 4 (4.30) 0 (0) 4 (2.08)
Manual 1 (1.08) 3 (3.03) 4 (2.08)
Office or standing 10 (10.75) 5 (5.05) 15 (7.81)
Time spent on feet
Most of the day 37 (32.74) 42 (36.21) 79 (34.5)
> 4 hours/day 29 (25.66) 26 (22.41) 55 (24.02)
< 4 hours/day 24 (21.24) 24 (20.69) 48 (20.96)
Not much time (mostly sitting) 23 (20.35) 24 (20.69) 47 (20.52)
Time spent driving
Most of the day 5 (4.42) 3 (2.59) 8 (3.49)
> 4 hours/day 7 (6.19) 3 (2.59) 10 (4.37)
< 4 hours/day 49 (43.36) 47 (40.52) 96 (41.92)
Just to/from work 46 (40.71) 47 (40.52) 93 (40.61)
Do not drive 6 (5.31) 16 (13.79) 22 (9.61)
a Includes all participants not studying.
b Includes all participants in employment, irrespective of working hours.
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Success of blinding
The results from the James et al.69 blinding index are given in Table 25 and indicate that, overall, participants
in this trial were completely blinded. However, the James et al.69 index automatically assumes that participants
reporting that they do not know their treatment allocation are reporting so honestly rather than to give a
response they perceive to be desired by their interviewer or to simply avoid making a judgement. Furthermore,
this index does not distinguish between treatments.69 To determine the effect of each treatment group and
ensure that ‘don’t know’ responses are taken into account, the Bang et al.70 index is also used to understand
blinding. The Bang et al.70 blinding index for the PRP group is positive, indicating that participants were more
TABLE 24 Clinical characteristics of participants, by intervention group
Clinical characteristics
Intervention group, n (%)
Total (N= 229), n (%)PRP (N= 113) Placebo (N= 116)
Medical condition in addition to tendon rupture
Heart disease 2 (1.77) 3 (2.59) 5 (2.18)
Hypertension 10 (8.85) 14 (12.07) 24 (10.48)
Asthma/COPD 22 (19.47) 13 (11.21) 35 (15.28)
Parkinson’s disease 0 (0) 0 (0) 0 (0)
Epilepsy 1 (0.88) 1 (0.86) 2 (0.87)
Liver disease 0 (0) 0 (0) 0 (0)
Stroke/mini-stroke (TIA) 3 (2.65) 0 (0) 3 (1.31)
Peptic ulcer 1 (0.88) 4 (3.45) 5 (2.18)
Cancer 6 (5.31) 3 (2.59) 9 (3.93)
DVT/pulmonary embolism 0 (0) 0 (0) 0 (0)
Osteoarthritis 7 (6.19) 4 (3.45) 11 (4.80)
Rheumatoid arthritis 3 (2.65) 4 (3.45) 7 (3.06)
Allergies 33 (29.20) 25 (21.55) 58 (25.33)
Othera 31 (27.43) 36 (31.03) 67 (29.26)
Number of comorbidities
0 44 (38.94) 56 (48.28) 100 (43.67)
1 36 (31.86) 28 (24.14) 64 (27.95)
2 20 (17.7) 23 (19.83) 43 (18.78)
> 2 13 (11.50) 9 (7.76) 22 (9.61)
Taking medication for pain or inflammation before injury
Yes 7 (6.19) 8 (6.90) 15 (6.55)
Nothing regular 19 (16.81) 17 (14.66) 36 (15.72)
No 87 (76.99) 90 (77.59) 177 (77.29)
Missing 0 (0) 1 (0.86) 1 (0.44)
COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic attack.
a Other medical conditions reported were cardiovascular (n = 5), endocrine (n = 5), gastrointestinal (n = 8), haematological
(n = 4), mental health related (n = 9), neurological (n = 2), physical musculoskeletal impairment (n = 23), respiratory
(n = 2), visual (n = 1) and other (n = 8).
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likely to guess that they received a PRP injection than that they received the placebo treatment. However,
the absolute value for this is < 0.2, indicating that blinding was likely to have been successful in this
treatment group. Conversely, the Bang et al.70 blinding index for the placebo group is negative, indicating
that participants were more likely than those in the control group to guess that they received the PRP
injection. However, as with the PRP group, the absolute value for this is < 0.2, indicating that blinding was
likely to have been successful in this group. Taking the information from both blinding indices into account,
there is no evidence to suggest that blinding in this trial was unsuccessful.
TABLE 25 The James et al. and Bang et al. blinding index results, including participants reporting ‘don’t know’ for
treatment allocation
Blinding index Index Standard error 95% CI
James et al.69 0.817 0.026 0.775 to 0.859
Bang et al.70
PRP group 0.144 0.066 0.036 to 0.252
Placebo group –0.179 0.055 –0.269 to –0.089
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